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ABSTRACT
ABSTRACT
Celiac disease (CD) is a relatively common autoimmune type of inflammation of the small
intestine also manifesting with various extraintestinal symptoms. The disease is triggered by
dietary gluten of wheat, barley and rye, but the pathogenetic mechanisms are not completely
resolved. The only established genetic risk factors so far are the human leucocyte antigens
(HLA) DQ2 and DQ8, either of which is carried by nearly all patients. HLA-linked genes can
not, however, explain the whole genetic susceptibility for this multifactorial disease. Several
attempts to localize the HLA-unlinked risk factors have included both genome-wide linkage
studies, as well as candidate gene approaches on positional or functional candidate genes,
and resulted in partly inconsistent results between the populations.
In this thesis we searched for the HLA-unlinked susceptibility genes of celiac disease. In
study I, two positional candidate regions 5q and 11q suggested in a previous Italian genome
scan were investigated in 102 Finnish families with affected sib-pairs. Evidence for linkage in
these regions was supported. The candidate region 15q26, reported to be linked with CD in
populations of the British Isles, was also tested (II), but no linkage in this region was observed.
Among the most interesting functional candidate gene loci for CD is chromosome 2q33,
harboring genes for the cytotoxic T-lymphocyte associated antigen 4 (CTLA4), CD28 and
inducible co-stimulator (ICOS). These molecules regulate the T-lymphocyte activation processes
and have been suggested to play a role in the pathogenesis of several autoimmune diseases.
Significant linkage of 2q33 with CD was observed, but no allelic association with the CTLA4
gene was found (III). A very high level of linkage disequilibrium between the widely studied
CTLA4 polymorphisms was found (IV), which is important to note in the search of the functional
risk allele primarily associated with the disease under study. The genome-wide linkage analysis
(V) on 60 Finnish families with affected sib-pairs suggested six HLA-unlinked susceptibility
loci; 1p36, 4p15, 5q31, 7q21, 9p21-23 and 16q12. The regions 4p, 5q and 7q were further
studied with additional markers and 38 additional CD families, but the linkage in these regions
was not markedly improved in the larger set of families. Although showing only suggestive
linkage, these regions located close to those reported previously at least in some independent
linkage studies. The strongest evidence from multiple studies has been accumulated to
chromosome 5q which harbors functionally relevant candidate genes encoding Th2 type
cytokines.
Consistent with other genome-wide scans in CD, the strongly linked HLA region at 6p21.3
appeared to be the major risk locus even in the Finnish population in which a founder effect
and lower level of heterogeneity can be assumed. Dose effect of the carried HLA risk alleles
was also supported in our family sample. Linkage heterogeneity in the candidate loci due to
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the disease phenotype and sex was suggested, and females carrying HLA-DQ2 in these
families had an increased risk of CD compared to males. This could implicate a possibly
stronger role of HLA-unlinked risk factors in families with affected males.
The relatively weak linkage evidence and the observed discrepancies between studies and
populations in the linked loci points either to a higher rate of false positive results, or a higher
level of heterogeneity or other confounding factors which are known to complicate the genetic
studies in multifactorial diseases. They also indicate that the HLA-unlinked loci are likely to
play only a minor and possibly a much more complex role in the CD susceptibility, which
further affects the power of available mapping methods. The figure is typical to most of the
other autoimmune diseases showing multifactorial etiology, and the problems and future tasks
for the genetic studies of these diseases are discussed.
12
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CELIAC DISEASE – GLUTEN SENSITIVITY
Celiac disease (CD, also known as gluten sensitive enteropathy, GSE, OMIM 212750) can be
defined as a permanent intolerance to dietary gluten, resulting in an autoimmune type of injury
in the small intestinal mucosa, and sometimes in other tissues, in genetically susceptible
individuals. The developing villus atrophy often leads to malabsorption of the nutrients and
various clinical symptoms. Thus far, the only cure is a strict, life-long gluten-free diet. The
pathogenesis of CD is partly unclear, but the immune system is assumed to play an important
role in it. Susceptibility to CD is inheritable, showing features of a complex or multifactorial
genetic disease. Confounding factors like genetic and phenotypic heterogeneity, epistasis and
gene-environment interactions typical to these diseases challenge the mapping of the genes
involved in them. The only susceptibility genes for CD established so far encode HLA-DQ
molecules, crucial players during immune activation. The search for other genes that would
explain the remaining genetic component of CD has recently started.
CLINICAL ASPECTS
Celiac disease was first described in 1888 by Samuel Gee who reported on chronic
malabsorption of ingested food and described many of the classical symptoms of CD (Gee,
1888). In infancy typical symptoms are chronic diarrhea, steatorrhea, abdominal distension
and failure to thrive (Schmitz, 1992), and in adult patients diarrhea, weakness, malaise and
weight loss (Howdle and Losowsky, 1992). Over the last few decades, however, the
gastrointestinal symptoms have become rarer, the clinical picture has been altered to milder
and atypical forms, and the age at diagnosis has increased (Mäki et al., 1988; Collin et al.,
1999). Diagnosis, which is based on small intestinal biopsy, disease-specific serum antibodies
and the clinical picture, can be made at any age. Several non-abdominal symptoms are
common, among which iron deficiency, short stature, delayed puberty, osteoporosis and dental
enamel defects may at least partly result from the malabsorption of nutrients. Furthermore,
infertility and miscarriages in women, liver diseases and neurological complications can be
found (Mäki and Collin, 1997). The reason for the relatively quick change in the clinical picture
must obviously be environmental – an effect of a longer period of breast feeding or timing of
gluten introduction to infant diet have been suggested (Auricchio et al., 1983; Ivarsson et al.,
2000). Other explanations are naturally the diagnostic improvement and the consequent
recognition of the milder and atypical forms of the disease.
13
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Celiac disease can also manifest in the skin as dermatitis herpetiformis (DH), an itching and
blistering rash which responds to gluten-free diet (Fry et al., 1973). Most DH patients have also
CD specific changes in their small bowel mucosa (Marks et al., 1966; Reunala et al., 1984).
Silent CD is an asymptomatic form of the disease, which is mainly diagnosed by screening
among e.g. first degree relatives of CD patients or other riskgroups. These patients have only
mild or no clinical symptoms at the time of diagnosis, but disease specific autoantibodies and
various degree of villous atrophy are usually found (Ferguson et al., 1993). Both DH and silent
CD can occur in families having patients with classical CD, and DH-CD monozygous twin
pairs have been described (Hervonen et al., 2000). This can indicate that the exact disease
manifestations are not solely dependent on genetic factors. However, this feature is difficult to
investigate, because once the gluten free diet has started it will effectively prevent the onset
of other forms of the disease.
Many autoimmune diseases co-occur with celiac disease. CD patients have an increased risk
to develop type I diabetes, Sjögren syndrome, autoimmune thyroid diseases and juvenile
rheumatoid arthritis (Cooper et al., 1978; Collin et al., 1994) and conversely, the risk of CD is
higher among patients suffering from these diseases (Collin et al., 1989&1994; Lepore et al.,
1996; Cronin et al., 1997; Sategna-Guidetti et al., 1998; Iltanen et al., 1999). At least tenfold
risk of CD have been observed among individuals with selective IgA deficiency compared to
population in general, and vice versa (Savilahti et al., 1971; Savilahti et al., 1985; Collin et al.,
1992; Cataldo et al., 1998). Interestingly, recent screening studies have confirmed the increased
risk of CD among patients with Down’s (Bonamico et al., 2001), William’s (Giannotti et al.,
2001) and Turner syndromes (Ivarsson et al., 1999), which makes the chromosomes 21, 7q
and X interesting as harboring potential candidate genes for CD, although the CD association
with these rare diseases can also be due to the severe metabolic unbalance and disturbed
immunity typical to these diseases.
The above mentioned associations between the autoimmune diseases and CD may be at
least partly due to the shared HLA susceptibility alleles associated with many of them. Other
shared genetic risk factors, such as the CTLA4 gene or its homologies on chromosome 2q33
may have a role in several autoimmune diseases (Kristiansen et al., 2000), and clustering of
genomic regions showing genetic linkage to autoimmune diseases has been observed (Becker
et al., 1998). Non-genetic factors like the prolonged pathophysiological immune activation
state may also decrease the overall threshold for autoimmunity. The risk of developing other
autoimmune diseases has been claimed to be higher in CD patients diagnosed in adulthood
(Ventura et al., 1999), which could indicate that long gluten exposure itself could predispose to
other autoimmune diseases. However, a recent study did not fully support this finding (Sategna-
Guidetti et al., 2001). Further studies on the role of gluten exposure in these diseases are
needed.
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DIAGNOSTICS
Wheat was identified as the dietary trigger of CD in 1950 by Willem-Karel Dicke (Dicke, 1950),
and the later studies also showed the toxicity of rye and barley (Anand et al., 1978). The
storage protein fraction of cereals contains gluten proteins, and the ethanol-soluble prolamins
of gluten are the triggering agents of CD. These prolamins are called gliadin in wheat, hordein
in barley and secalin in rye. In the late 1950’s the diagnosis of CD was also improved by the
introduction of a method for small intestinal biopsies (Shiner, 1957). The European Society for
Paediatric Gastroenterology and Nutrition (ESPGAN) provided criteria for CD diagnosis in
1970 which included an observed villus atrophy during normal gluten containing diet, and the
healing of the small bowel mucosa during gluten-free diet (Meeuwisse, 1970). The original
requirement of a third biopsy after gluten-rechallenge is not supported nowadays, but the
small bowel biopsy is still the gold standard of the diagnosis. In developing celiac disease the
first histological change in the small intestinal mucosa is the infiltration of the epithelium and
subsequently the lamina propria by lymphocytes. This is followed by the hyperplasia of the
crypts, with partial, subtotal and finally total villous atrophy, leading to the flat mucosa typical
to CD (Marsh, 1992).
The diagnosis of celiac disease is also supported by specific serum antibody tests. These
tests are useful also to monitor the strict adherence to a gluten-free diet, as well as in screening
and in the search for silent CD patients among first degree relatives and other risk groups
(Troncone and Ferguson, 1991; Mäki, 1995; Dieterich et al., 2000). IgA- and IgG-class anti-
gliadin-antibodies (AGA) were the first diagnostic antibodies recognized and are still widely
used, although their sensitivity and specificity to celiac disease is low (Stern, 2000). Instead,
the novel tests for autoantibodies against extracellular matrix components show higher sensitivity
and specificity. Methods for detecting IgA-class anti-reticulin- (ARA) and anti-endomysium-
(EMA) antibodies are available, together with tests for autoantibodies against tissue
transglutaminase (tTG) which is now known to be the major autoantigen for the endomysial
antibodies (Dieterich et al., 1997).
EPIDEMIOLOGY
Celiac disease is a relatively common disease in European populations, affecting all age
groups. It is twice as common in females than in males (Logan, 1992), also a typical feature of
many other autoimmune diseases. The prevalence in Europe was earlier estimated to be 1/
1000, although regional differences were found (Greco et al., 1992). Several recent screening
studies revealing the previously undiagnosed patients with silent CD, have however indicated
a higher prevalence of even 1/100 (Catassi et al., 1994; Johnston et al., 1997; Kolho et al.,
1998; Meloni et al., 1999; Korponay-Szabo et al., 1999). The inability to pick up the milder
15
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forms probably explains why CD was earlier reported to be rare in USA, although the prevalence
of DH was similar to Europe (Smith et al., 1992). Recent screening studies have indeed shown
prevalence of 1/250 in USA (Not et al., 1998). Environmental factors such as early exposure
to gluten, the amount of gluten intake and the duration of breast feeding may induce fluctuation
in the incidence of clinical CD among infants (Ivarsson et al., 2000). Whether the overall
prevalence of CD among the population is affected by these factors when asymptomatic
patients among all age groups are included is still an open question.
PATHOGENESIS
Pathogenesis of the mucosal lesion in celiac intestine is still partly unknown, although strong
evidence points to the T-lymphocyte mediated immune mechanisms, with activation signs of
both cellular and humoral responses (Schuppan, 2000). The strong, almost absolute association
of CD with HLA-DQ2 and DQ8 suggests that the disease-causing antigen is presented by
these molecules (Sollid and Thorsby, 1993). In the intestinal biopsies from CD patients, but
not those from controls, CD4+ T-lymphocyte clones reactive to gliadin can be found. Furthermore,
these T-lymphocytes recognize the gliadin peptides presented by DQ2 or DQ8, but not by
other HLA alleles (Lundin et al., 1993&1994; Molberg et al., 1997). The proinflammatory Th1
type of cytokines secreted by these activated T-lymphocytes could then drive the mucosal
damage either directly or by indirect effects on upregulation of HLA expression on enterocytes,
activation of cytotoxic T-lymphocytes, increased Fas expression on epithelial cells leading to
their apoptosis (Maiuri et al., 2001) or secretion of matrix degrading enzymes by fibroblasts
(Pender et al., 1997). The number of intraepithelial lymphocytes bearing the γδ-T-lymphocyte
receptor is increased in both CD and DH patients (Halstensen et al., 1989; Savilahti et al.,
1992), but their role in the pathogenesis is unknown.
Several DQ2 or DQ8 specific epitopes among gliadin peptides have been found (Sjöström et
al., 1998; van de Wal et al., 1998b; Anderson et al., 2000; Arentz-Hansen et al., 2000).
Interestingly, the T-lymphocyte recognition of most of them depends on an enzymatic modification
by tissue transglutaminase (tTG). tTG plays a multifunctional role in the stabilization of the
extracellular matrix and in tissue repair, and its extracellular activity is increased during
inflammation and in the celiac mucosa (Molberg et al., 2000).  tTG appears to play a dual role
in celiac disease (Figure 1). It strongly enhances the antigenicity of the gliadin peptides by
deamidation of glutamine residues into glutamic acid (Molberg et al., 1998; van de Wal et al.,
1998a). tTG is also the major autoantigen against which the highly specific autoantibodies
observed in the sera of untreated CD patients are directed (Dieterich et al., 1997). tTG can
form cross-links between proteins by covalent bonds between lysin and glutamine residues
and the tTG-gliadin complexes have been proposed to direct the autoimmune antibody formation.
According to one hypothesis (Sollid et al., 1997), these complexes could be taken up by B-
16
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lymphocytes specific for tTG, resulting in the processing and presentation of both tTG and
gliadin peptides by these cells. The help from gliadin-specific T-lymphocytes, which accumulate
in celiac intestinal mucosa, could then drive the anti-tTG antibody secretion by these B-
lymphocytes. The role of anti-tTG antibodies in the pathogenesis of CD is unclear. Preliminary
evidence exists that they could block the essential function of tTG in the proteolytic activation
of transforming growth factor (TGF)-β. This could then disturb the epithelial cell differentiation
which is dependent on TGF-β (Halttunen and Mäki, 1999).
Due to the strong HLA-association and the formation of autoantibodies, celiac disease presents
many features of an autoimmune disease. Compared to many other disorders of this type, CD
can indeed serve as a relatively simple model disease for them. The autoantigen (tTG), the
highly specific autoantibodies against it and the functional role of the associated HLA-molecules
in the disease pathogenesis have been characterized. Importantly, the major environmental
trigger, gluten, is also known and encountered practically by all individuals. However, celiac
disease can not be strictly defined as a classical autoimmune disease since the loss of
immunologic tolerance to the self-antigen is secondary and dependent on gluten.
Figure 1. Dual role of tissue transglutaminase (tTG) in celiac disease. tTG can both (1) deamidate
specific gliadin peptides enhancing their binding affinity to DQ2 molecules, and (2) form complexes
between itself and gliadin. These complexes could drive the autoantibody production by tTG specific
autoreactive B-lymphocytes, with the help from gliadin specific, DQ2 (or DQ8) restricted T-helper
lymphocytes.
B
tTG
Th
ANTI tTG
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GENETICS OF CELIAC DISEASE
Celiac disease is a typical multifactorial disease in which both several genetic and environmental
factors are needed for the disease onset. The familial component is evident, the disease
prevalence among the first degree relatives is 10% (Ellis, 1981; Mäki et al., 1991), giving the
relative risk of 10, when assuming the prevalence of 1/100 in the general population. Speaking
in favor of genuine genetic susceptibility is the fact that the concordance among monozygous
twins has been reported to be over 70% (Polanco et al., 1981; Bardella et al., 2000) and two
recent studies reported an even higher figure (Hervonen et al., 2000; Greco et al., 2002).
Among dizygotic twins the concordance is only 11% which is at the same level as the risk for
siblings (Greco et al., 2002). The concordance among monozygous twins appears one of the
highest in the field of complex diseases - and it might even be higher if the subjects were
followed for a longer time, since the age at onset can vary in terms of decades between twins.
The only definitive genetic risk locus thus far is human leucocyte antigen (HLA) DQ at the
major histocompatibility complex (MHC) on chromosome 6p21.3.
MAJOR HISTOCOMPATIBILITY COMPLEX AND HLA-MOLECULES
The main function of the adaptive immune system is to effectively recognize foreign antigens
and to eliminate pathogens, at the same time still maintaining tolerance for self antigens and
normal flora. The capability of the immune system to recognize a huge number of antigenic
peptides, processed and presented by antigen presenting cells (APC), is based on the variability
in highly polymorphic HLA genes encoding molecules with slightly different antigen binding
specificities. These HLA-antigen complexes are recognized by T-lymphocyte receptors, which
are also extremely polymorphic.
HLA genes are among the most polymorphic genes known in man, and they all are located
within a gene cluster called the major histocompatibility complex (MHC) spanning 4 megabases
(Mb) on chromosome 6p21.3 (Figure 2). The MHC region harbors over 200 genes (The MHC
sequencing consortium, 1999) of which many, but not all are related to the function of the
immune system. The region can be divided into three classes: the telomeric part carries the
class I HLA genes A, B and C, and the centromeric part the genes encoding the class II HLA-
antigens DR, DQ and DP (Trowsdale, 1996). The class III MHC region harbors a diverse
collection of genes, many of which are involved in the immune system, e.g. the cluster of
genes encoding many components of the serum complement system (Aguado et al., 1996).
Both class I and II HLA-antigens are transmembrane molecules characterized by an extracellular
peptide binding groove (Figure 3). The amino acid variability between the HLA-alleles is
concentrated in the residues constructing this groove, which is relevant in respect to the
18
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ability of the HLA molecules to bind a variety of antigenic peptides. The class I HLA-molecules
HLA-A, -B and –C are heterodimers composed of one transmembrane α-chain, which is encoded
by HLA locus and features three extracellular domains and a non-polymorphic β2-microglobulin
(β2m) encoded by a non-HLA locus. Domains α1 and α2 of the α-chain form the groove, which
binds antigenic peptides, typically 8-10 amino acids in length. Class II HLA molecules DR, DQ
and DP are heterodimers of one α- and one β-chain, α1 and β1 domains forming the peptide
binding groove. Both the α- and β-chains are encoded by HLA-linked genes. The class II
molecules bind peptides which are up to 20 amino acids in length.
The class I HLA-molecules are expressed by nearly all cell types. By these molecules, cells
present intracellularly synthesized peptides to cytotoxic CD8+ T-lymphocytes, therefore
monitoring the pathogenic changes due to viral infections or transformation of the cell. Instead,
Figure 2. Location of the HLA genes within the MHC gene cluster on chromosome 6p21.3.
Figure 3. Structure of HLA class I and II molecules. The
extracellular domains forming the antigenic peptide (Ag)
binding groove are illustrated. APC, antigen presenting cell.
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the expression of class II HLA molecules is mainly restricted to professional antigen presenting
cells of the immune system, such as macrophages, monocytes, B-lymphocytes and dendritic
cells. Class II molecules bind extracellular antigens taken in and processed by these cells and
present the HLA-antigen complex to CD4+ T-helper lymphocytes. The T-lymphocytes then
guide the cell-mediated (Th1 type) or humoral (Th2 type) immune response against the
extracellular pathogens, such as bacteria or dietary components.
The multiple HLA genes with highly variable alleles form a broad range of alternative HLA
genotypes, or tissue types, of an individual. Along with the additional variation due to trans
combinations of class II heterodimers in heterozygotes, the HLA system defines the range of
antigens against which the immune reactions can be targeted. On the other hand, HLA molecules
have a key role in tolerance induction to the body’s self antigens, breakage of which could
cause a pathogenic autoimmune attack against self proteins and tissues. The repertoire of
mature T-lymphocytes, which present a huge variety of T-lymphocyte receptors (TcRs) for
effective recognition of pathogens, is defined in the thymus: the potentially autoreactive T-
lymphocytes, which react exceptionally strongly with HLA-self peptide complexes presented
by thymocytes are eliminated during their maturation.
HLA-ASSOCIATED DISEASES
Certain HLA alleles are found to be associated with diseases, either in a protective or
predisposing manner (Hall and Bowness, 1996). Most of these diseases are autoimmune
disorders. Several hypotheses have been made to explain these associations. First, the distinct
binding properties of HLA molecules could cause differences in the strength of peripheral
immune response to some critical antigen. Second, these binding differences between the
alleles could affect the tolerance induction to a certain self peptide in the thymus. Third,
molecular mimicry between the pathogenic and self peptides may cause an autoimmune
reaction triggered by infection. Fourth, the pathogen may also use certain HLA molecule as a
receptor, although no convincing evidence for this is available. Finally, the association may
also result from the strong linkage disequilibrium (LD) between the associated HLA allele and
a closely located primary risk gene. This is the case for example in hereditary hemochromatosis
(Feder et al., 1996) or congenital adrenal hyperplasia (White et al., 1984). An exceptionally
high level of LD characterizes the MHC region, i.e. certain alleles exist in the same haplotypes
far more frequently than expected by their allelic frequencies.
HLA-LINKED GENES IN CELIAC DISEASE
Strong linkage disequilibrium can complicate the fine-mapping of disease associated genes.
HLA association of celiac disease was confirmed in 1972, when a significant excess of alleles
20
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HLA-A1 and HLA-B8 were found in patients, compared to healthy controls (Falchuc et al.,
1972; Stokes et al., 1972). Soon after, an even stronger association was found for class II
region allele Dw3 (presently DRB1*03), which often coexists with HLA-B8 (Keuning et al.,
1976; Ek et al., 1978). Later, alleles DR7 (DRB1*07) and DR5 (DRB1*11) were also found to be
associated (DeMarchi et al., 1979; Mearin et al., 1983; Trabace et al., 1998). Today, the primary
associated locus has been proven to be HLA-DQ; this is based both on functional and genetic
evidence (Sollid, 2000).
HLA-DQ2 molecule associates with CD in all studied populations, being one of the strongest
HLA associations among autoimmune type diseases. In most populations, over 90% of CD
patients carry the DQ2 heterodimer encoded by alleles DQA1*05 and DQB1*02 (Sollid and
Thorsby, 1993). DQ2 can be formed in cis, i.e. both DQA1 and DQB1 risk alleles are located in
the same chromosome (Figure 4). The DQ2 cis haplotype is more frequent among CD patients
of Northern Europe, and this haplotype invariably carries also the DRB1*03 allele. In Southern
Europe the DQ2 molecule is also frequently formed in trans in individuals heterozygous for
haplotypes DRB1*11-DQA1*05-DQB1*03 and DRB1*07-DQA1*02-DQB1*02. Most of the CD
patients negative for DQ2 carry either the DRB1*04-DQB1*0302 (DQ8) haplotype or they are
positive for only one of the alleles coding for DQ2 (Spurkland et al., 1992; Polvi et al., 1998).
Although one copy of DQ2 is sufficient for disease onset, a dose dependence of DQ2 molecule
has been observed (Ploski et al., 1993; Congia et al., 1994). Interestingly, individuals
heterozygous to DRB1*03 and DRB1*07 haplotypes have been claimed to be at a higher risk
of CD than the DRB1*03-DQ2 homozygotes, suggesting that in addition to two copies of
DQB1*02 present in both genotypes, an additional risk factor in the DRB1*07 haplotype might
be present (Meddeb-Garnaoui et al., 1995; Fernández-Arquero et al., 1995). One suggested
Figure 4. DR-DQ haplotypes carrying the DQA1 and DQB1 alleles which encode the α and β chains,
respectively, of the heterodimers DQ2 and DQ8 associated with celiac disease.
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candidate (Clot et al., 1999b) was the DRB4 gene (DR53), which is also present in the DRB1*04-
DQ8 haplotype (Figure 4), but the genetic data do not completely support the DRB4 hypothesis
(Partanen, 2000). Some DPB1 alleles have also showed preliminary association to CD (Polvi
et al., 1996), and haplotype transmission tests from DQB1*02 homozygous parents to affected
offspring have suggested different transmission patterns, suggesting that additional DQ2 linked
risk factors might exist (Polvi et al., 1997; Lie et al., 1999; Karell et al., 2002). Even if these
non-DQ risk factors in the HLA region existed, the DQ2 molecule still has the major functional
role in pathogenesis. Also, the concordance studies among twins and HLA identical sibs
clearly demonstrate that HLA unlinked risk factors are needed for disease onset.
HLA-UNLINKED GENES IN CELIAC DISEASE
Although the alleles HLA-DQ2 or -DQ8 are needed for the onset of celiac disease, they cannot
explain the whole genetic susceptibility of the disease. First, they are both common in healthy
individuals showing carrier frequencies of 22% and 24% in the Finnish population, respectively
(Partanen and Westman, 1997). Second, over 70% concordance among monozygous twins is
one of the highest among complex diseases (Polanco et al., 1981; Hervonen et al., 2000;
Bardella et al., 2000; Greco et al., 2002), pointing to strong genetic impact and leaving only
minor space for variation in environmental risk factor(s) other than gluten. However, in siblings
sharing identical HLA haplotypes the CD concordance is only around 30%, suggesting
importance of genes located outside HLA in disease susceptibility (Mearin et al., 1983;
Petronzelli et al., 1997). The contribution of HLA factors to the entire familial risk to develop
CD has been estimated to be only 1/3, which includes both genetic and environmental factors
shared by family members (Rotter and Landaw, 1984; Risch, 1987; Petronzelli et al., 1997;
Bevan et al., 1999).
GENETIC ANALYSES OF COMPLEX GENETIC DISEASES
All genetic linkage and association analyses basically test the correlation of a given phenotype
with the given genotype. Since this correlation is very strong or even complete for the diseases
caused by a single gene and showing simple dominant or recessive inheritance pattern, the
identification of the genetic cause of these Mendelian disorders is nowadays a relatively
straight-forward task. The gene affected usually carries a number of mutations, each resulting
in a defective function of protein and causing the characteristic phenotype of the disease.
Instead, the defining of the genetic basis of common, multifactorial diseases is much more
complicated (Lander and Schork, 1994; Risch, 2000).
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GENETIC CHALLENGES OF MULTIFACTORIAL DISEASES
Several factors complicate the identification of the individual susceptibility genes of complex
traits. First, the diseases are typically multifactorial, i.e. several environmental and genetic
factors are involved in the disease onset. Second, epistatic interaction between these
susceptibility genes as well as gene-environment interactions are likely to exist. Third,
heterogeneity for the genetic factors occur between, and even within, populations. This
heterogeneity can be either allelic, i.e. the disease phenotype is influenced by different allelic
variants of the same gene, or locus heterogeneity, i.e. susceptibility alleles of alternative
genes can result in the same phenotype. Due to these factors, it is likely that the genetic
factors determine only the general susceptibility to the disease, but can not directly cause it.
This means that different genetic backgrounds can result in the same phenotypic trait. Therefore,
the specific risk attributable to a single gene may be dependent on, e.g. environmental factors,
or allelic variation in other genes.
These underlying confounding factors in multifactorial diseases affect the power of available
statistical methods for genetic studies. The inheritance model can not be accurately determined
from the segregation of the disease in families. Also, the correlation between the phenotype
and the given genotype at a single locus is likely to be low due to two phenomena: the
penetrance of a single susceptibility allele is nearly always incomplete, meaning that only
part of the carriers are affected; and on the other hand, phenocopies are common, i.e. individuals
affected without the susceptibility allele. Furthermore, the frequency of this allele in a population
can not be a priori estimated by the frequency of the disease, which is possible for monogenic
traits.
In addition to this hidden genetic variability within a phenotype of multifactorial disease, the
phenotype itself can show large differences. The spectrum and the severity of symptoms can
vary between the patients even within a single family. This complicates the setting of the affection
status in genetic analyses, since prior knowledge of whether this variation is due to genetic or
environmental differences is not usually available. Setting of the disease phenotype for the analysis
is also complicated if the age at disease onset lies within a large scale; the unaffected family
members at the time of the study can develop the disease in later life. For some traits, the
availability of quantitative measurements associated with the disease, such as serum cholesterol
level in coronary disease or serum IgE levels in asthma, can overcome this problem at least to
some extent. Here the phenotype tested is in a quantitative scale, instead of the qualitative,
dichotomous affection status where the individuals are classified either affected or unaffected.
One should however, bear in mind that the tested single quantitative measure might not correlate
fully with the disease itself. Furthermore, it can be difficult to obtain an accurate and comparable
measurement of all tested individuals since its value might be strongly dependent on non-genetic
factors such as the treatment of the disease and age.
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DEFINING THE GENOTYPES
The genetic studies of a given trait need polymorphic markers for identification of the genotype
of an individual on the chromosomal region of interest. This genotypic information can be used
in association studies between patient and control groups and in linkage approaches in which
inheritance patterns of chromosomal regions are followed within families. With family data, the
haplotypes, i.e. alleles physically located in the same parental chromosomes can also be
constructed if the genotypes of multiple markers in the region are determined.
The first polymorphic markers used were the blood group antigens, followed by serum proteins
and HLA antigens. In the 1980’s, genetic linkage studies underwent a revolution as the use of
restriction fragment length polymorphisms (RFLP) was discovered (Kan and Dozy, 1978). By
these dimorphic, single nucleotide polymorphisms (SNPs), which occur randomly and very
frequently in the genome with an average distance of 1 kilobase (kb), the genetic studies were
not anymore restricted to a few regions. Subsequently, the first human genetic map was
constructed for RFLP markers (Donis-Keller et al., 1987). The next type of markers discovered
were DNA minisatellites, a variable number of tandem repeats (VNTR) of 14-100 base pair (bp)
segments (Bell et al., 1982; Jeffreys et al., 1985). Compared to RFLPs these were more
informative for linkage analysis due to multiple alleles, although their large size (>1000 bp)
complicates their genotyping.
The most widely used genetic markers today are the DNA microsatellites, another type of
VNTR’s, also known as single tandem repeats (STR) and simple sequence length polymorphisms
(SSLP) (Weber and May, 1989; Litt and Luty, 1989). Microsatellites are very polymorphic
tandem repeats of short, 1-6 nucleotide long segments, typically with a high number of alleles
differing in the repeat number. They are very frequent and regularly dispersed in the genome;
the most widely studied (CA)
n
 dinucleotide repeats are found at distances of about 30 kb
(Hearne et al., 1992). With the development of polymerase chain reaction (PCR) and automated
genotyping technologies, a quick and easy high-throughput genotyping of them has become
possible. Due to their high informativity and the availability of dense marker maps for them
(Dib et al., 1996), the use of microsatellites has become a standard approach in most genetic
analyses today. The mutation rate of microsatellites is higher than other sequences of the
genome on average, resulting from slippage during DNA replication which creates alleles with
insertions or deletions in the repeat number (Jin et al., 1996). The functionality of microsatellites
is unclear, since they are not usually located in the coding regions of the genes. However,
some genes contain these repeats in non-coding sequence like 5' or 3' untranslated regions,
where in theory they could have an effect on the regulation of mRNA expression or stability.
Indeed, expansion of intragenic trinucleotide repeats have been recognized as a major cause
certain neurological disorders (Lieberman and Fischbeck, 2000).
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The use of single nucleotide polymorphisms have in the past few years become popular again
(Nowotny et al., 2001). Although not as informative as microsatellites, SNPs have several
advantages. They are far more frequent in the genome and due to a lower mutation rate they
are more stable, which is advantageous in linkage disequilibrium based approaches. The wide
existence of SNPs in the coding regions of genes also makes them the functional candidate
polymorphisms for disease susceptibility. Novel efficient genotyping techniques have recently
been developed for SNPs, including the DNA hybridization chips, which would allow extremely
large throughput, and the use of SNP panels instead of microsatellites in genomic analyses in
the future has been suggested (Kruglyak, 1997).
GENOME-WIDE SCREENINGS AND CANDIDATE GENE APPROACHES
Identification of disease genes for monogenic traits has been successful with a systematic
screening of the whole genome by polymorphic markers, followed by the standard linkage
analysis in families. For complex diseases the results between independent genome-wide
studies have often been contradictory, pointing to the confounding factors complicating the
studies of these traits (Risch, 2000). A widely used approach is to first genotype the genome
for 350-450 microsatellites. The most interesting regions are often studied further with a denser
set of markers and replicated in an independent set of families. Since the average inter-marker
distance is – due to practical and economical reasons - as long as 10 centiMorgans (cM), the
rate of a false negative result in the genome-wide linkage analysis is high. An alternative is to
focus the search on small genomic regions, where plausible candidate genes for the disease
are located. The candidates can be e.g. known genes with an assumed functional relevance in
the disease pathogenesis, or positional candidate regions suggested by previous genome-
wide screenings. In the candidate gene approach, denser sets of markers and larger sets of
families can be studied which decrease the chance of a false negative result. However, the
genome-wide analysis is the only way to reveal novel regions carrying susceptibility genes,
for which no prior assumptions as functional candidates could be made. The significance of
the original finding is then easy to test in independent study samples by candidate approaches
in these regions.
GENETIC LINKAGE ANALYSES
The term genetic linkage refers to the non-independent segregation of two marker loci in
families, i.e. the probability of meiotic recombination is less than 50% (Morgan, 1911). The
measure of linkage is the genetic distance or recombination fraction θ (theta). When two loci
are located so close to each other that no recombinations are observed, the linkage is complete
and θ = 0. Linkage is absent and θ = 0.5 when the loci are segregating independently, located
far enough from each other or in separate chromosomes. The measure of map distance between
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two genetic loci is Morgan (M); 1 cM (centiMorgan) corresponds to θ = 0.01 in small distances.
In longer distances the probability of multiple recombinations between the loci in a single
meiosis is higher, and the conversion of recombination fractions to the map distances has to
be corrected by Haldane’s or Kosambi’s map functions. A map distance of 1 cM roughly
corresponds to a physical distance of 1 Mb.
Parametric linkage analysis
If the disease parameters such as the inheritance model, disease gene frequency, penetrance
and phenocopy frequency are known for the disease, as they usually are for monogenic diseases
following the Mendelian dominant or recessive inheritance, the most powerful linkage analysis
is the traditional logarithm of odds (LOD) score method (Morton, 1955). The inheritance of
marker alleles is followed in large pedigrees with multiple affected individuals. The test calculates
the likelihood L of linkage between the genetic marker and the phenotype with a given
recombination fraction θ. The observed likelihood is compared to the likelihood of the null
hypothesis of no linkage (θ = 0.5). The LOD score is the ten based logarithm of this likelihood
ratio. The test uses both genotype and phenotype information of all available family members
and the distance between the studied marker locus and the “genuine” risk locus can be estimated.
The power of the test is highly sensitive to the disease parameters, which are however usually
impossible to accurately estimate for a multifactorial disease.
Non-parametric linkage analysis
For the linkage analysis of complex diseases, methods not relying on the estimates of the
disease parameters have been developed. They measure the degree of allele sharing between
affected sib-pairs (ASP), or all affected relative pairs (ARP) (Shih and Whittemore, 2001). The
observed sharing in families is compared to the sharing probability assuming no linkage. If the
marker locus is not linked to the disease locus, the proportions of affected sib-pairs sharing
two, one or none of the parental alleles identical by descent (IBD) will not differ significantly
from the expected 0.25, 0.50 and 0.25 by chance, if a sufficient number of families are studied.
The statistical significance of the sharing excess can be estimated by the χ2 test with 2
degrees of freedom. Sharing information can be increased by using markers with a high level
of heterozygosity, genotyping several adjacent markers for multipoint linkage analysis and
genotyping unaffected siblings especially if one or both parents are unavailable. Current test
programs can use estimates of the IBD sharing based on marker allele frequencies and some
programs use only identical by state (IBS) sharing information. Among the most widely used
non-parametric analyses are the maximum likelihood score method (MLS) and the non-
parametric linkage (NPL) which are included e.g. in the MAPMAKER/SIBS and GENEHUNTER
program packages (Kruglyak and Lander, 1995; Kruglyak et al., 1996; Markianos et al., 2001).
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Meta-analysis of genome-wide screenings
Since the individual genome screenings are usually performed with a limited number of families,
because of both availability of families and the high cost of genome-wide mapping, the combined
analysis of data from independent genome screenings would be an attractive way to increase
the sample size and power to detect risk loci with a modest effect on the disease. This is
however, complicated by different marker sets used in the studies, and too often the reluctance
of researchers to give access to the raw genotype data. Combining and comparison of the
results of individual studies is also problematic, since their magnitude is highly dependent on
the study design, i.e. size and pedigree structure of the study sample and the statistical
method used. To overcome these problems, several meta-analysis methods have been
developed. In genome search meta-analysis (GSMA) the chromosomes are divided into bins
of certain length which are then ranked according to their linkage scores (Wise et al., 1999).
The bin ranks of each screening study can be then compared and combined. Some type of
meta-analysis might prove to be critical for identification of the genes with only a modest
effect. On the other hand, combining data showing locus heterogeneity between populations
can in fact decrease the overall evidence in regions with a true positive result in some
populations. The problem of publication bias towards positive findings is common among
studies on complex diseases, which is also important to take into account when collecting
data for meta-analysis and interpreting the results.
GENETIC ASSOCIATION ANALYSES
In addition to linkage analyses, the candidate genes can be studied for allelic association.
Indeed, the primary susceptibility gene in a genomic region linked with the disease can not be
specified by the linkage evidence alone. The linked region, often 10-20 cM in length, can even
carry hundreds of genes, among which the one(s) primarily and functionally associated with
the trait must be searched for. Instead, the chromosomal region in linkage disequilibrium with
the susceptibility gene, and therefore detectable by association analyses, is often only a few
centiMorgans. However, as opposed to linkage analysis, the power of association tests is
affected by allelic heterogeneity, which may require substantially larger samples to be tested.
Two basic approaches are in use: case-control and family-based association studies (Risch,
2000; Cardon and Bell, 2001).
Case-control approach
Population based association tests compare the allele or genotype frequencies between groups
of unrelated patients and independent unaffected controls. The χ2 based test is powerful, but
the risk of false positive results is high because differences in allele frequencies can also be
due to different ethnical background. Careful matching of the control group by age, sex and
origin are therefore needed.
27
REVIEW OF THE LITERATURE
Family-based association tests
To overcome the matching problem of case-control studies, methods using family-based controls
have been developed (Schaid and Sommer, 1994; Zhao, 2000). The most widely used test is
the transmission/disequilibrium test (TDT), a χ2 based test for association and linkage, comparing
the transmissions vs. non-transmissions of the marker allele from heterozygous parents to
affected offspring (Spielman et al., 1993; Spielman and Ewens, 1996). TDT can also be applied
for multiple affected siblings but then it is not however, a valid test for association, but can be
used as a linkage test. Several extensions of TDT have been developed, which use haplotypic
information from multiple markers and sibling genotypes to compensate missing parents. In
addition, unaffected controls with parents can be applied to control for spurious significant
results due to segregation distortion (Scott and Rogus, 2000).
STATISTICAL SIGNIFICANCE
A traditional criteria for a significant linkage result for single tested locus was a LOD score of
≥3 (p=0.0001) (Chotai, 1984). Since hundreds of markers tested in any single genome-wide
analysis increase the chance of false positive result, a genome-wide significance level of LOD
3.3 was suggested (Lander and Kruglyak, 1995). The interpretation of linkage studies on
multifactorial traits is however more complicated. The obtained linkage scores do not typically
reach these significance levels at all. Different kinds of analyses are often performed on the
same data in order to ensure not overlooking linkage, which further decreases the significance
due to multiple testing corrections. Therefore, the interpretation of the linkage results of a
complex disease is not whether the evidence for linkage is definitive or not, but rather whether
it is promising enough for follow-up studies, e.g. LOD above 1 or 2. The succeeded replication
of the linkage evidence, even if again only suggestive, in independent samples, can then
confirm the true linkage in the region. However, this can not be applied conversely, i.e. failure
to replicate the linkage does not necessarily indicate that the original result was false positive,
since true heterogeneity for susceptibility genes between the study samples may exist (Risch,
2000).
The significance of association tests often performed for multiple markers carrying multiple
alleles may also need to be corrected. However, the Bonferroni correction, where the nominal
significance is multiplied with the number of tested alleles or markers is very conservative.
This is especially the case for neighboring tightly linked markers for which the allelic associations
may not be independent. The computational progresses among genetic tests have offered
many sophisticated simulation based approaches to cope with the problem of multiple testing
(McIntyre et al., 2000).
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GENOMEWIDE SCREENINGS AND CANDIDATE GENE APPROACHES
IN CELIAC DISEASE
GENOME-WIDE ANALYSES
In order to identify novel non-HLA susceptibility loci to celiac disease, five independent genome-
wide screenings and several replication studies have been reported so far, including the studies
in this thesis. The results are compared further in Table 6 of Discussion. Despite the strong
linkage to the HLA region, the findings in other regions are only suggestive and partly
controversial between the studies.
The first genome scan in the western counties of Ireland analyzed 15 families with 40 affected
sibs (Zhong et al., 1996). In addition to the HLA region which demonstrated strong linkage to CD,
six other regions were reported to yield suggestive evidence for linkage including 6p (non-HLA),
7q31, 11p11, 15q26, 19q and 22cen. Subsequently, the non-HLA regions implicated from the Irish
study were re-examined by Houlston et al (1997) and Brett et al (1998) using independent sample
sets. While the former study showed moderate linkage evidence in the 15q26 region, the latter
study did not find any linkage evidence for these regions. The region 15q26 is of particular interest
since it harbors a susceptibility gene (IDDM3) for type I diabetes as well (Field et al., 1994). We
tested this region for linkage to celiac disease in publication II of this thesis.
The second study analyzed 39 Italian sib-pairs genome-wide and a larger sample of 110 sib-
pairs for specific regions (Greco et al., 1998). Suggestive evidence for linkage was found on
chromosome 5q. The analysis of a subset of 39 sib pairs in which both siblings manifested a
symptomatic form of CD, provided suggestive evidence for linkage to chromosome 11q as
well. Interestingly, this finding was not observed in the remaining 71 sib pairs where one sib
displayed symptomatic CD and the other had the silent form of CD. Recently, by analyzing an
independent sample set, Greco et al (2001) have presented further evidence in support of
linkage to chromosome 5q but not to chromosome 11. In study I we investigated the linkage in
5q and 11q candidate regions in Finnish families with CD.
The third genome screening with 16 multiplex UK families (King et al., 2000) reported putative
linked loci at 10q and 16q and supporting evidence for linkage to 6q, 11p and 19q, three
suggested regions in the first genome scan from Ireland. Lower LOD scores were also found in
several other regions. The follow-up study on 17 candidate regions supported linkage at 6p12,
11p11, 17q12, 18q23 and 22q13 (King et al., 2001).
The recent fourth study with Swedish and Norwegian families revealed nominally significant
linkage in 8 non-HLA regions, 2q11-13, 3p24, 5q31-33, 9p21, 11p15, 11q23-25, 17q22 and
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Xp11 (Naluai et al., 2001). The whole genome analysis was performed on 70 families with
affected sib-pairs and the linked regions together with 5 other candidate gene regions were
studied with a larger set of 106 families. The stratification of families according to the HLA risk
allele dose strengthened the linkage evidence in the CTLA4 candidate gene region at 2q33.
Finally, we studied 60 Finnish families genome-wide in publication V with subsequent follow-
up of three selected regions by additional markers and families.
CANDIDATE GENES
Several functional candidate genes have been studied for an association or linkage with celiac
disease. The studies are summarized in Table 5 of Discussion. Most of the candidates are
players in the immune system that can be assumed to be involved in CD. The other candidates
are the genes related to digestive processes and antigen modification, the gene encoding the
autoantigen tTG and genomic regions involved in CD-associated diseases. Up to now, the
only functional candidate region with increasing evidence of linkage or association with CD is
the chromosome 2q33 carrying genes for cytotoxic T-lymphocyte associated antigen –4 (CTLA4),
CD28 and inducible costimulator (ICOS). These are all important regulators of T-lymphocyte
activation and therefore relevant candidates of CD with T lymphocyte mediated pathogenesis.
CANDIDATE GENES CD28, CTLA4 AND ICOS ON CHROMOSOME 2q33
The antigen-specific signal needed for T-lymphocyte activation is delivered through the binding
between the MHC molecule on the antigen presenting cell and the T-lymphocyte receptor on T-
lymphocytes. The subsequent immune activation for the antigen requires however, a second
signal through the costimulatory molecules such as B7 and CD28 (Lenschow et al., 1996;
Bugeon and Dallman, 2000). B7-1 (CD80) and B7-2 (CD86) are transmembrane molecules
expressed on professional antigen presenting cells (Figure 5). Their ligand CD28 is constitutively
expressed on naive, resting T-lymphocytes. Together with the antigen specific signal, the ligation
of B7 molecules with CD28 induces the T-lymphocyte proliferation and effector functions by
enhanced expression of T-lymphocyte activating cytokine interleukin-2 (IL2), its receptor and
anti-apoptotic molecules. Activation of T-lymphocytes also induces the cell membrane expression
of CTLA4 molecule, which shares high homology with CD28 and binds B7-1 and B7-2 with
much higher affinity. In resting T-lymphocytes, CTLA4 can only be found intracellularly, but
after transportation into the cell membrane during the activation, CTLA4 starts to compete
with CD28 for the B7 ligands. Therefore, CTLA4 confers an inhibitory effect on the lymphocyte
activation and proliferation. The negative regulatory effect is thought to be due both to the
competitive inhibition and to the negative signaling cascade induced (Thompson and Allison,
1997; Lee et al., 1998). The crucial role of CTLA4 in controlling autoreactivity has been
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demonstrated by CTLA4 knock-out mice suffering from a massive lethal lymphoproliferation
(Tivol et al., 1995; Waterhouse et al., 1995). The role of a recently characterized new member
of the CD28/CTLA4 family, inducible costimulator (ICOS), in the immune system is largely
unknown, but it seems to be a regulator of Th2 type response and antibody formation (Linsley,
2001).
The genes for CD28, CTLA4 and ICOS are located adjacent to each other on chromosome
2q33 (Ling et al., 2001). This region has been found to be linked to several autoimmune
diseases including type I diabetes, CD, multiple sclerosis (MS) and autoimmune thyroid diseases
(Kristiansen et al., 2000). The CTLA4 gene, the most widely studied candidate of this region,
has three known genetic polymorphisms (see Figure 7 in results), which in several studies
have been associated with autoimmune diseases. Two of them are single nucleotide
polymorphisms: -318*C/T in the promoter region (Deichmann et al., 1996) and +49*A/G in the
first exon coding for leader peptide of the protein, which leads to Thr -> Ala substitution of
codon 17 (Nisticó et al., 1996). A polymorphic AT-repeat region – microsatellite CTLA4(AT)
n
 –
is located in the 3' untranslated region of the last exon (Polymeropoulos et al., 1991). Any of
these polymorphisms could be assumed to alter the expression level or function of CTLA4.
Indeed, in vitro evidence of decreased inhibitory function of CTLA4 has recently been shown
for allele +49*G (Kouki et al., 2000) and for CTLA4(AT)
n
 alleles with long repeat regions (Huang
et al., 2000). However, the ultimate identification of primary functional polymorphism within a
small segment of DNA can readily be complicated by linkage disequilibrium. In publication IV,
we studied the level of LD between the three polymorphisms of the CTLA4 gene.
Figure 5. T-lymphocyte activation and co-stimulation. In addition to the antigen specific signal through
the HLA-antigen complex and the T lymphocyte receptor (1), the activation of T lymphocyte requires
co-stimulatory signals. One of them is delivered by B7-1 or B7-2 receptors expressed by professional
antigen presenting cells (APC) and their CD28 ligand on T lymphocyte (2). This two-signal activation
allows the proliferation of the T lymphocyte clone and maturation of the effector Th1 or Th2 cells,
which can subsequently drive the cell-mediated or humoral immune responses, respectively. The
activation process is down-regulated by the increased cell surface expression of the CTLA4 molecule
which has a higher affinity to the shared B7 ligands than CD28 (3).
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Evidence for a novel susceptibility locus at 2q33 has also been presented for celiac disease.
A French case-control study by Djilali-Saiah et al (1998) presented the first evidence for the
CTLA4 association. The frequency of allele A of +49*A/G polymorphism was significantly
higher among celiac patients than in the control group. In study III of this thesis, we found
evidence for genetic linkage between seven markers at 2q33 and celiac disease in 100 Finnish
CD families.
32
AIMS OF THE STUDY
AIMS OF THE STUDY
In the present thesis the genetic susceptibility to celiac disease was studied in Finnish multiplex
families, with the following specific aims:
1. To evaluate the genetic linkage and association of the candidate regions 2q33 (CTLA4/
CD28), 5q, 11q and 15q26 with CD (I-III) and to determine the strength of linkage disequilibrium
within the CTLA4 gene (IV).
2. To study the presence of linkage heterogeneity due to disease phenotypes and sex in the
candidate regions (I).
3. To evaluate the role of HLA-DQ2 in the studied families, with a specific respect in the effect
of the dose and sex on the susceptibility to CD (I, V).
4. To screen the whole genome for novel susceptibility loci for celiac disease (V).
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STUDY ETHICS
The families studied in this thesis were collected on a voluntary basis through the Finnish
Coeliac Society by advertising in the patients’ newsletter. The study protocol has been accepted
by the Ethical Review Board of Tampere University Hospital (permission number 95173).
STUDY SUBJECTS
The recruited 137 volunteering families with at least two affected members were accepted for
further evaluation. The earlier diagnoses were re-evaluated by scrutinizing the medical records.
Healthy family members were screened for antiendomysium antibody positivity and 6.2% of
them were found to have an asymptomatic form of the disease (Mustalahti et al., 2002).
Families with at least two affected siblings were used in the linkage studies of this thesis (I-III,
V). Table 1 shows the number of families and patients in these studies, according to the
number of available affected siblings and parents studied. These samples were overlapping
sets from a total of 103 families; one of the 100 families in study III was excluded from the
other studies due to uncertain identity of one DNA-sample. Haplotypes in study IV were
determined from all available founder individuals in a total of 156 families; in addition to the
102 families overlapping with studies I-III and V, 54 additional families were studied. These
also included families collected for earlier studies and are described in detail by Polvi et al
(1996). Among the 98 families in study V, the diagnosis based on a small bowel biopsy was
obtained for all but 17 of the 256 patients, for which no definitive evidence from the biopsy was
available. 35 patients had dermatitis herpetiformis and 20 were asymptomatic patients found
by screening the family members. Median age at the time of diagnosis was 37 years. All
families were of apparent Finnish origin and there was no evidence of any particular clustering
in their current places of residence.
Table 1. Structure of Finnish families with at least one affected sib-pair studied for publications I-III and
V. The family samples represent overlapping sets from a total of 103 families.
Study Number
of
Affected siblings Available parents Total of
patients
families 2 3 4 2 1 0
I 102 71 24 7 42 27 33 263
II 99 69 24 6 39 27 33 253
III 100 75 20 5 39 28 33 250
V (stage 1) 60 39 16 5 19 20 21 159
V (stage 2) 98 67 24 7 42 24 32 256
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GENETIC MARKERS
All polymorphic microsatellites were genotyped with fluorescence based detection systems of
PCR-products using ABI 310 and 377 Sequencers (Applied Biosystems, Foster City, CA).
Microsatellites genotyped in candidate region 2q33 (III) were D2S2392, D2S2214, D2S116,
CTLA4(AT)
n
, D2S2189 and D2S2237, at 5q (I) D5S410, D5S422, D5S2032, D5S425, D5S2069
and D5S2111, and at 11q (I) D11S898, D11S4111, D11S4142, D11S976, D11S4171, CD3D
(Mfd69CA, dinucleotide repeat within CD3D gene), D11S934 and D11S910. Two SNPs within
the CTLA4 gene (III-IV) were genotyped by the PCR/RFLP method using the primers
5’TTACGAGAAAGGAAGCCGTG, 5’AATTGAATTGGACTGGATGGT and MseI-digestion for
CTLA4-318*C/T and the primers 5’AACCCAGGTAGGAGAAACAC,
5’GCTCTACTTCCTGAAGACCT and BbvI-digestion for CTLA4+49*A/G  polymorphism, with
subsequent agarose gel electrophoresis. Genotypic data in the candidate regions were checked
for Mendelian errors and for unexpected double recombination events within small genetic
distance, using multipoint analysis of Genehunter-plus v1.1 or Genehunter 2.0 program versions
(Kruglyak et al., 1996). The genotypes most likely to be erroneous were either retyped or
removed from the analyses. The genome-wide screening (V) was performed with 352
microsatellites with an average marker distance of 9.6 cM, and the genotypic data was examined
for possible error sources in Mendelian consistency and biological relationships using the
Pedcheck (O’Connell and Weeks, 1998) and the RelCheck computer programs (Broman and
Weber, 1998), respectively. Primer sequences for all microsatellites (except the CTLA4(AT)
n
)
and the genetic distances between the markers were obtained from public marker databases
of Genethon (www.genethon.fr), the Genome Database (www.gdb.org), and the Marshfield
Genetic Laboratory (research.marshfieldclinic.org/genetics). The genotyping of the marker
CTLA4(AT)
n
 was performed using the primers 5’GTGATGCTAAAGGTTGTATTGC and
5’AAAACATACGTGGCTCTATGCAC.
HLA TYPING
The HLA-DQB1 alleles were genotyped from all available family members using a DQ SSP
“Low Resolution” kit (Dynal AS, Oslo, Norway). Major classes of the HLA-DQB1 alleles, including
the known susceptibility alleles DQB1*02 (DQ2) and DQB1*0302 (DQ8) could be determined.
Based on our unpublished results, about 90% of DQB1*02 positive individuals in Finnish
families with celiac disease have the DQA1*05 DQB1*02 haplotype.
DATA ANALYSIS
The linkage in the candidate gene regions (I-III) was tested with the Genehunter-plus v1.1 and
the Genehunter 2.0 program versions (Kruglyak et al., 1996). Multipoint NPL
all or MLS scores
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were reported. The heterogeneity between the MLS results of the phenotypical subgroups of
the families (I) was tested using the M-test (Morton, 1956), which compares the linkage results
in the subgroups a and b with the linkage in the whole sample (a+b) as χ2 statistics 2ln(10)
[MLS(a)+MLS(b)-MLS(a+b)]. The significance of the test result was assessed by 10000
replicates of randomized division of the whole sample in subgroups with sizes equal to the
original subgroups, with following linkage and M-tests. The proportion of these simulated test
results exceeding the observed value was set as the simulated p-value.
The transmission/disequilibrium test (TDT) for the candidate regions was performed by the
Genehunter 2.0 (I-II) and Sib-Pair 0.95.3 (III) programs (Kruglyak et al., 1996; Duffy, 1997). For
a valid association test, only one affected offspring in each family was tested (I-II). For both
one and two locus TDT, the significance of the test result was obtained by the permutation
option in Genehunter 2, to correct the effect of the testing of multiple markers with multiple
alleles (I-II).
Allelic association in the publication III was tested in 100 families using the Sib-Pair 0.95.3
version (Duffy, 1997). Allelic frequencies were compared between all affected and unaffected
family members by the Pearson goodness-of-fit based test. To correct the bias in nominal P-
values due to relatedness of individuals within families, an empirical P-value was estimated
by the Monte-Carlo simulation using 10000 iterations.
Linkage disequilibrium was calculated by the Arlequin program (Schneider et al., 1997) for a
given set of independent three-locus haplotypes in the publication V. Haplotypes were
constructed by the Genehunter 2.0. An exact test of LD between 3 pairs of markers and the
standardized disequilibrium value D’ for each of the allele pairs among the marker pairs were
calculated. Values of D’ range from –1.0, stating that the alleles never occur together, to
complete disequilibrium 1.0, through 0 stating for no LD between the alleles.
Genome-wide linkage analysis (V) was performed using a pseudomarker approach (Göring
and Terwilliger, 2000a; Göring and Terwilliger, 2000b) by the FASTLINK program (Cottingham Jr
et al., 1993). Two dominant and two recessive models of inheritance were tested, one with high
penetrance (0.90) and the other with very low penetrance (0.0007). No phenocopies were
allowed and the disease allele was assumed to be infinitesimally rare, according to the
pseudomarker strategy (Göring and Terwilliger, 2000b). Multipoint analyses of the three follow-
up regions of the genome scan were conducted by joining the meiotic information from two
neighboring markers (i.e. the three-point analysis), using only the genetic model yielding the
highest lod score in the two-point analysis of the region. Multipoint NPL
all statistics for the 60
families were calculated genome-wide by Genehunter 2.0 (unpublished data).
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LINKAGE IN CANDIDATE REGIONS 2q33, 5q, 11q AND 15q26 (I-III)
The candidate region 2q33 harboring the CTLA4, CD28 and ICOS genes was studied since it
shows association or linkage to several autoimmune diseases (Kristiansen et al., 2000) and at
the time of the study, an allelic association with celiac disease was also reported (Djilali-Saiah
et al., 1998). The studied chromosomal regions 5q and 11q were the candidates suggested in
the genome-wide analysis by Greco et al (1998). The region 15q26 was studied as it was
reported to be linked with CD in two previous studies (Zhong et al., 1996; Houlston et al.,
1997), and may also confer genetic susceptibility to type I diabetes (Field et al., 1994).
The highest non-parametric linkage results, either MLS or NPL
all scores with nominal p-values,
for the four studied candidate regions are summarized in Table 2. Details of the studied markers
are shown in the original publications I-III. In the total set of families, suggestive evidence for
linkage was found for 5qter (p=0.03), 11q23 (0.01) and 2q33 (p=0.006). On the other hand, no
evidence for linkage between 15q26 and celiac disease was observed.
ASSOCIATION AND TDT RESULTS ON CANDIDATE GENES
At 2q33, an association was found between CD and marker D2S116 located 0.3 cM centromeric
to CTLA4. Allele 136 bp was present in 5% (23/476) of the chromosomes of all patients
compared to 12% (19/162) among all genotyped healthy individuals (χ2 9.35, p=0.0022) and
the difference remained significant after Bonferroni correction for 8 tested alleles of D2S116
(p=0.018). Association of this marker with celiac disease was significant (p=0.0001) also with
the simulation approach which corrects the relatedness of the tested family members. The
same allele D2S116*136 showed negative maternal transmission with the transmission/
Table 2. Linkage between celiac disease and the candidate gene regions 2q33, 5q, 11q, 15q26 in
Finnish families with affected sib-pairs.
Region Families
studied
Markers
studied
Length of
the region
(cM)
Marker
with the
highest
score
Test
statistics
p-value
(nominal)
2q33 (III) 100 7 3.3 D2S116 NPL
all 2.55 0.006
5q (I) 102 6 34.5 D5S2111 MLS 0.88 0.03
11q (I) 102 8 48.3 D11S4142 MLS 1.37 0.01
15q26 (II) 99 5 19.9 D15S642 NPLall -0.07 0.53
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disequilibrium test (1 transmitted versus 11 non-transmissions, nominal p<0.05). None of the
other six tested markers at 2q33 showed association with CD.
No evidence for allelic association was found for markers on 5q. Instead, TDT supported
linkage between CD and the 5 adjacent markers in region 11q23. In the single locus test, allele
D11S4171*131 showed preferential transmission to affected offspring (21 transmitted versus
7 not transmitted, nominal p=0.008) and nominally significant scores were obtained for all four
adjacent marker pairs. The haplotype D11S4171*131-CD3D*82 also showed evidence of allelic
association with CD when only one affected sib from each family was analyzed. However,
none of the TDT statistics remained significant after the permutation approach to correct for
multiple testing.
While the NPL analysis for markers at 15q26 revealed no evidence for linkage with CD, a
preferential transmission of the allele D15S107*1 for the affected offspring was found (20
transmissions vs. 5 non-transmissions, nominal p=0.003). The difference remained significant
after the permutation test as well (0.03). In the two-locus TDT, the haplotype D15S107*1-
D15S120*6 was transmitted 14 times, compared to 2 non-transmissions (nominal p=0.003,
permutated p=0.058). No particular shared feature in HLA-DQ status, geographical origin, or
disease phenotype was found for families carrying this haplotype.
LINKAGE HETEROGENEITY (I)
Heterogeneity for linkage results between the phenotypic subgroups of the families was tested
in the candidate regions 2q33, 5q and 11q. Two divisions could be made, still maintaining
sufficiently large subgroups for linkage analysis: disease manifestation and sex of the affected
siblings. For this, linkage was tested separately in 33 families with at least one patient affected
by dermatitis herpetiformis (DH) and in the remaining 69 families with no DH patients, and in
56 families with at least one affected male sibling and in 46 with only affected female sibs.
Figure 6 shows the results which varied widely between the subgroups. Linkage to 2q33 was
only found in families with no DH patients (CD group) and conversely, the families with DH
patients showed linkage to the 5q and 11q markers (DH group). In all three regions, linkage
was detected in those families with at least one male patient (FM group), whereas the family
group with only females affected (FF group) showed no linkage to these regions. The only
statistically significant difference with the M-test between the subgroups was for the FM and
FF division at 5q (simulated p=0.019). The linkage at HLA region was also tested with the
DQB1 genotype data. Extremely strong linkage with MLS of 14.3 (p=10-16) was observed in a
total sample of 102 families, and the linkage was highly significant in all the tested subgroups,
MLS varying from 3.8 to 10.9.
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Figure 6. MLS scores in the candidate regions 2q33, 5q and 11q in the whole group of families and
in the subgroups. A total set of 99 (2q33) or 102 (5q, 11q) families (group ALL) were divided into
subgroups DH and CD, based on the presence or absence of patients with dermatitis herpetiformis in
the families, respectively. Another division for FM and FF groups was based on the presence or
absence of male patients among the affected siblings in the families, respectively. Only 10 families
contained male patients with no affected females, and they were included in the FM group.
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LINKAGE DISEQUILIBRIUM WITHIN THE CTLA4 GENE (IV)
Two previous studies showed that variations in the CTLA4 gene may affect the inhibitory
function of CTLA4 in the activation of T-lymphocytes (Kouki et al., 2000; Huang et al., 2000).
As these authors concentrated on two separate variations, we studied the strength of linkage
disequilibrium between all three known polymorphisms within the gene. LD was tested among
577 independent haplotypes constructed from a total of 156 non-related Finnish families with
celiac disease (Figure 7). An exact test of linkage disequilibrium showed a highly significant
level of LD between all three marker pairs (p=0.00). Two common haplotypes were observed: -
318*C; +49*G; CTLA4(AT)
n
*99 bp with a frequency of 37% and -318*C; +49*A; CTLA4(AT)n*81
bp with a 30% frequency, showing a high level of LD between the alleles at +49*A/G and
CTLA4(AT)
n
 (D’ = 0.95 and 0.89, respectively). The other allelic combinations showed much
lower frequencies (0.2 – 6.0%) and are presented in Table I of the original publication IV.
Figure 7. Linkage disequilibrium between the CTLA4 gene markers. Genomic organization of the
CTLA4 gene (not in scale) is shown as    for coding regions and as    for the untranslated regions of
exons. The relative positions of the three known polymorphisms are marked with arrows. P-values of
the exact test of LD between marker pairs, and D’ values and frequencies for the two most common
allele combinations are shown.
 
                -318  +49      CTLA4(AT)n
                 C/T   A/G       81…131 bp
Exact test of LD:      p=0.00
     p=0.00
     p=0.00
Standardized
disequilibrium (D'):
Frequency
(n=577)
D'
(C) G 99 bp 216 (37%) 0.95
(C) A 81 bp 174 (30%) 0.89
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GENOME-WIDE LINKAGE STUDY (V)
Figure 8 shows the pseudomarker LOD scores of all the chromosomes tested over the four
inheritance models in the 60 families affected by CD. Highly significant linkage for all the
models was found on chromosome 6p21 overlapping the HLA region (LOD scores between
4.63 and 5.96 for the marker D6S1281). Six non-HLA regions 1p36, 4p15, 5q31, 7q21, 9p21-23
and 6q12 showed suggestive evidence for linkage with maximum LOD scores over 1.00 (1.02
- 2.11), as presented in Table 3. A follow-up study with a denser marker set and 38 additional
CD-families was performed for three of these regions: 4p15 was selected due to its highest
LOD score of 2.11, and 5q31 and 7q21 due to the reported linkage evidence close to these
regions in the two previous genome-wide studies. These regions were analyzed using the
model which yielded in the best linkage score in the genome-wide analysis, and the two- and
three-point results for the original set of 60 and the combined set of 98 families are shown in
Table 3. Although the three-point analysis with dense marker set yielded stronger evidence for
linkage at 4p15 (LOD 3.25) and consistent evidence at 5q31 and 7q21, the addition of families
did not strengthened the evidence in any of the three regions.
Table 3. LOD scores over 1.0 obtained for the six non-HLA regions in the genome-wide analysis and
in the follow-up study of three of these regions. Only the highest scores among the four inheritance
models are shown; either with dominant or recessive inheritance for a gene with high or low penetrance.
Multipoint NPL
all scores with nominal p-values in the same six regions are presented for comparison,
as well as the linkage results for other regions of interest: two suggested in studies I and III and two
reaching nominally significant linkage only with NPL
all statistics. From the follow-up analysis, the
results from markers yielding the highest linkage scores are reported. nd, not determined.
Genome-wide
analysis
Follow-up analysis
60 families 60 families 98 families
Locus Marker Model
Two-point
LOD
Multipoint
NPL
all (p)
Two-
point
Three-
point
Two-
point
Three-
point
REGIONS WITH LOD>1
1p36 D1S3669 Dom/High 1.09 1.60 (0.06) nd nd nd nd
4p15 D4S2639 Dom/Low 2.11 2.33 (0.01) 2.14 3.25 1.78 2.40
5q31 D5S816 Rec/High 1.72 1.47 (0.07) 1.72 1.50 1.81 1.52
7q21 D7S821 Dom/High 1.02 1.09 (0.14) 1.01 1.04 0.84 1.02
9p21-23 D9S741 Rec/Low 1.11 1.76 (0.04) nd nd nd nd
16q12 D16S3253 Rec/Low 1.40 1.79 (0.04) nd nd nd nd
OTHER REGIONS OF INTEREST
11q (I) D11S2002 Dom/High 0.20 0.93 (0.18) nd nd nd nd
2q33 (III) D2S1361 Dom/Low 0.47 1.30 (0.10) nd nd nd nd
4q26 D4S3250 Dom/Low 0.54 2.14 (0.02) nd nd nd nd
15q11 D15S165 Dom/Low 0.82 2.18 (0.02) nd nd nd nd
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Figure 8. Genome-wide linkage in the 60 celiac disease families. Maximum LOD scores are shown for the four tested models with either high
or low penetrance and dominant or recessive inheritance.
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Table 3 also shows the highest multipoint NPL
all statistics for the suggested six non-HLA
regions in 60 families (unpublished data). The results were consistent with the LOD scores,
varying from NPL
all 1.09 to 2.33. Only markers on chromosomes 4p, 9p and 16q showed
nominally significant (p<0.05) results. Both statistics are also shown for four other interesting
regions. 11q and 2q33 showed linkage in the candidate studies I and III, but no linkage was
observed in the genome-wide analysis. Chromosomal regions 4q26 and 15q11 reached
nominally significant NPL
all results but remained undetected in the pseudomarker analysis
with LOD scores under 1.0.
SUSCEPTIBILITY TO CELIAC DISEASE DUE TO HLA FACTORS (I, V)
All available members of the 102 studied families were genotyped for the HLA-DQB1 alleles.
Our unpublished results have shown that over 90% of the DQB1*02 positive patients in Finland
carry the common DRB1*03 – DQA1*05 – DQB1*02 risk haplotype (often referred to as DR3-
DQ2). For simplification, all DQB1*02 positive were therefore considered as DQ2 risk molecule
carriers, in the absence of data for DQA1 alleles at the time of the studies. Among the 98
families used for the genome-wide scan (V), 252 of the 260 patients carried DQ2, seven were
negative for DQ2 but carried the DQ8 risk molecule and only one patient was negative for both
DQ2 and DQ8.
Table 4 shows the disease prevalence among all DQ2 positive family members, as well as
among those with either a single or double dose of DQ2. In addition, division by sex is shown.
65% of all DQ2 carriers were affected by celiac disease. The CD prevalence was higher (79%)
in individuals with two copies of DQ2, compared to the heterozygous carriers (60%). Since the
individuals tested were not genetically independent, testing of the statistical significance for
this difference, suggesting dose dependence of risk due to DQ2, can not be regarded as valid.
CD prevalence among DQ2 carriers also differed between the sexes. 71% of all DQ2 positive
females in the families were affected, compared to only 52% of males (Fischer exact p=0.0001).
The tested individuals were genetically related in this comparison as well, but as the sex of
patients is not dependent on parental HLA genotypes, the test result can be regarded as
suggestive evidence for sex-dependent risk of CD due to HLA-DQ2.
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Table 4. Prevalence of CD among all family members due to the HLA-DQ2 risk allele. The dose effect
of DQ2 was studied in 98 families (V) and the sex-specific risk among DQ2 positive family members
in overlapping 102 families (I). *p=0.0001
Affected Unaffected CD prevalence
Overall prevalence
    All DQ2+ 252 137 65%
Dose effect
    DQ2 single dose 175 117 60%
    DQ2 double dose 77 20 79%
Sex effect
    DQ2+ females 176 71 71%*
    DQ2+ males 84 79 52%*
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DISCUSSION
In the studies of this thesis, we investigated genetic susceptibility to celiac disease due to
HLA-unlinked genes. We concentrated on the functionally interesting CTLA4/CD28 gene region
on chromosome 2q33 (III) and on the previously suggested candidate gene regions 5q, 11q
and 15q26 (I-II). The whole genome was screened for novel susceptibility loci for CD (V). In
addition, linkage heterogeneity for the candidate gene regions was further studied between the
disease phenotypes and sex, and the sex- and dose-related roles of HLA risk factors in celiac
disease were investigated (I, V).
CANDIDATE GENES IN CELIAC DISEASE
Several linkage and association studies have been performed for HLA-unlinked functional
candidate genes of CD (Table 5). The results of the five genome-wide screenings and subsequent
replication studies are summarized in Table 6. Among the functional candidates involved in
immune responses are the genes encoding the T-lymphocyte activation regulators CTLA4,
CD28 and ICOS, their ligands B7-1 and B7-2, T-lymphocyte receptor (TcR), the CD4 antigen
and the GM allotypes encoded by the genes for immunoglobulin heavy chain constant regions.
Other studied functional candidates are the genes for the CD autoantigen tissue transglutaminase
(tTG), two ectopeptidases dipeptidylpeptidase IV (DPP4) and aminopeptidase N (APN) involved
in digestive processes, and the candidate gene regions due to CD-associated diseases, such
as the susceptibility loci in type I diabetes and the chromosomes 7q11 and 21 involved in
Williams’ and Down Syndromes, respectively. The 2q33 region carrying genes for CD28, CTLA4
and ICOS can be regarded as the most promising functional candidate region in CD. Instead,
evidence in other regions is poor, despite weak evidence for the TcR-γ gene (Arai et al., 1995)
and GM allotypes (Bouguerra et al., 1999). It should be noted however, that most of the older
studies were case-control approaches with relatively small sample sizes. In these studies the
chance of false positive or negative result is likely to be higher than in the family-based
linkage and/or association studies. The family-based studies have been marked with asterisks
in the Table 5.
At the time of study III, an association between celiac disease and allele CTLA4+49*A had
been reported by a case-control approach performed in the French population (Djilali-Saiah et
al., 1998). We studied both family-based linkage and association for seven markers at 2q33 in
a total of 100 multiplex families (III). Linkage in this region was statistically significant (p=0.006).
However, no allelic association for the two studied CTLA4 gene polymorphisms could be
detected, and therefore the association of CTLA4+49*A in the French population was not
confirmed in our study. Instead, allelic association was observed with marker D2S116 located
close to the CTLA4 gene. The results indicate that the gene region may carry a genuine risk
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factor of CD. This has also been supported by two other recent studies in Scandinavian families
which interestingly also showed association with the CTLA4+49*A allele (Torinsson-Naluai et
al., 2000; Popat et al., 2002). Another study with British families also showed linkage at 2q33
(King et al., 2002). As in our study, no association was found with CTLA4 gene markers, but
instead with D2S2214, a microsatellite marker adjacent to the D2S116 and CTLA4 gene. It is
of note that the possible association between allele A at CTLA4+49 marker and celiac disease
differs from other autoimmune diseases such as type I diabetes, autoimmune thyroid diseases
and rheumatoid arthritis in which association with allele G has been frequently observed
(Kristiansen et al., 2000). This suggests that the susceptibility factor in this gene region might
differ between celiac disease and the other disorders, although the primarily associated gene
and polymorphism still remains to be determined for all of them.
Although the evidence for a susceptibility factor to autoimmune diseases on chromosome
2q33 is clear, many discrepancies of linkage evidence or associated alleles still exist between
the studies. The lack of linkage may indicate either true heterogeneity between the studied
Table 5. Studies on HLA-unlinked functional candidate genes in celiac disease. *Family based studies
for linkage and/or association.
CANDIDATE GENE REGION POSITIVE EVIDENCE NO EVIDENCE
2q33
CTLA4, CD28, ICOS
Djilali-Saiah et al (1998)
Holopainen et al (1999)* (III)
Torinsson-Naluai et al (2000)*
King et al (2002)*
Popat et al (2002)*
Clot et al (1999)*
Neuhausen et al (2001)*
3q13-21  B7-1, B7-2 Ali-Varpula et al (2002)*
7p15-14, 7q35, 14q11
TcR genes (α, β, γ or δ)
Arai et al (1995) TcR-γ Roschmann et al (1993)*
Roschmann et al (1995)*
Roschmann et al (1996)*
Yiannakou et al (1999)*
Neuhausen et al (2001)*
12pter-12  CD4 Neuhausen et al (2001)*
14q32
GM Ig-allotypes
Kagnoff et al (1983)
Carbonara et al (1983)
Weiss et al (1983)
Rautonen et al (1990)
Caruso (1991a,b)
Mazzola (1992)
Bouguerra et al (1999)*
Fedrick et al (1985)
Hetzel et al (1986)
Hannigan et al (1991)
20q11  tTG van Belzen et al (2001)*
2q23 dipeptidylpeptidase IV (DPP4)
15q25-26 aminopeptidase N (APN)
Clot et al (2000)*
15q26(IDDM3), 11q23(IDDM4),
6q25(IDDM5), 18q21(IDDM6),
6q27(IDDM7), 3q22-25(IDDM9), 10p11-
q11(IDDM10)
Neuhausen et al (2001)*
Susi et al (2001)* 15q26 (II)
7q11.23  Williams Syndrome locus Grillo et al (2000)*
chromosome 21  Down Syndrome locus Morris et al (2000)*
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populations or false negative results which are likely to be common in multifactorial diseases.
Two candidate gene studies on celiac disease have also failed to show linkage or association
to 2q33, one performed in Italian and Tunisian families (Clot et al., 1999a) and the other in
North American families (Neuhausen et al., 2001). Interestingly, any evidence for linkage on
chromosome 2q was found neither in our genome-wide screening (V) nor in the first two genome-
wide studies (Zhong et al., 1996; Greco et al., 1998). The strength of linkage in this region was
also weak in the genome screen by King et al (2000). The study in Swedish and Norwegian
families showed linkage at 2q11-13, a region located as far as 80 cM centromeric from 2q33
(Naluai et al., 2001). Their subsequent stratification analysis suggested linkage at 2q33 in a
subgroup of families with a single dose of the HLA-DQ2 risk molecule. However, their earlier
finding of allelic association of CTLA4+49*A with CD (Torinsson-Naluai et al., 2000) was not
strengthened in this subgroup. The discrepancy between the genome-wide and candidate gene
approaches in chromosome 2q33 can indicate the increase of power in candidate gene studies
usually performed with denser marker sets and a larger number of families, which was also the
case in our studies. Denser marker sets also allow the application of methods based on
linkage disequilibrium. Good examples of the advantages of these methods have been shown
for other complex diseases as well. The linkage and association between type I diabetes and
its candidate genes for insulin (11p15) as well as for CTLA4, have been successful with TDT-
type approaches, while the traditional linkage analyses at these loci have shown discrepancies
even with large data sets (Spielman et al., 1993; She and Marron, 1998).
Linkage disequilibrium often complicates the identification of which polymorphism confers the
primary functional susceptibility. The best known example is the MHC gene cluster showing
very strong LD which can lead to almost equivalent disease associations of several genes
present in the same conserved haplotype. In the candidate region 2q33, most of the genetic
studies in autoimmune diseases have concentrated on three available polymorphisms in the
CTLA4 gene and revealed somewhat discrepant results on the disease-associated
polymorphisms. Recently, two studies showed that genetic variation in the CTLA4 gene can
have an effect on the downregulatory function of CTLA4 on activated T lymphocytes. Huang et
al (2000) studied the CTLA4(AT)
n
 microsatellite 3’ untranslated region and found a decreased
inhibitory function of CTLA4 in individuals carrying alleles with a high number of repeats. A
similar effect was found by Kouki et al (2000) in individuals who carried the G allele at
CTLA4+49*A/G polymorphism leading to Ala->Thr amino acid change in the leader peptide of
CTLA4. In study IV we showed in a large sample of Finnish haplotypes that linkage disequilibrium
between the three known CTLA4 polymorphisms is extremely high. For example, the most
frequent allele with high number of repeats CTLA4(AT)n*99bp nearly always occurred with the
allele CTLA4+49*G in a common haplotype with a frequency of 37% in Finland. Our study
demonstrated that the identification of the primary functional polymorphism can not be done
by studying only one polymorphism at a time. Therefore, either more detailed haplotype analyses
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or in vitro mutagenesis approaches are needed, since all three CTLA4 polymorphisms are
functionally relevant candidates. This is supported by a recent functional study on all three CTLA4
polymorphisms which interestingly showed a differential expression of CTLA4 due to the genotype
at the promoter variation (Ligers et al., 2001). As this marker was not included in the studies by
Huang et al (2000) or Kouki et al (2000), any conclusions of the primarily functional polymorphism
can not be drawn yet. The role of other closely linked and functionally related genes, such as
CD28 and ICOS, can not be excluded either. Furthermore, no prior assumption can be made for
only one polymorphism or one of these genes to confer susceptibility to autoimmune diseases.
Studies on all these genes are therefore justified with specific respect in the linkage disequilibrium
between them. We have recently screened the human ICOS gene for polymorphisms to be used
in genetic studies (Haimila et al., 2002) and our unpublished results show that LD is significant
between these three genes in the Finnish celiac families. Controversially, no LD was found between
CD28, CTLA4 and ICOS in the Japanese population (Ihara et al., 2001). This can either result
from the differences in the sample type and selected markers between the studies, or from the
higher level of LD in the Finnish population featuring a founder effect which points to the relevance
of LD measurement in all populations under study in the future.
In addition to the candidate region on 2q33, evidence for the susceptibility loci for CD on
chromosomes 5q and 11q is also accumulating. Our results of the study I supported the  genetic
linkage in these regions as originally suggested by Greco et al (1998). Although these authors
could not confirm the linkage at 11q in a larger family sample (Greco et al., 2001), weak evidence
for linkage at 11q was found also in studies by King et al (2000&2001). Interestingly, the genome
screen on Swedish and Norwegian families supported linkage at 5q and 11q as well (Naluai et al.,
2001). The region 11q23 linked with CD in our study carries several functional candidate genes
involved in the immune system, such as the interleukin-10 receptor gene and genes encoding
three CD3-complex chains. The region also harbors genes for matrix metalloproteinases MMP-1
and MMP-3, expression of which is increased in the untreated celiac mucosa and which may be
involved in the pathogenetic process of CD (Daum et al., 1999). In our study, the linkage was also
supported by a preferential transmission to patients of certain haplotypes within this gene region.
The original report by Greco et al (1998) suggested that this locus could distinguish the symptomatic
and silent forms of celiac disease. Unfortunately, this could not be tested in our families due to
the small number of families including sibs affected with silent CD. Despite the linkage evidence
in our candidate gene approach, no linkage on 11q was detected in our genome-wide study. This
can be due to a higher false negative rate in genome-wide studies performed in a restricted
number of markers, and in our case also with smaller number of families.
Instead, both our candidate gene study (I) and the genome-wide screening (V), supported the
positive linkage on chromosome 5q suggested in two previous genome-wide studies by Zhong et
al (1996) and Creco et al (1998). The follow-up study by Greco et al (2001) strenghthened the
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linkage in the Italian population and in addition, the results of the other Scandinavian genome-
wide study by Naluai et al (2001) and an unpublished meta-analysis of four European genome-
wide linkage results have supported well the linkage in this region. Although the regions with the
strongest linkage to 5q did not completely overlap between these studies, the most interesting
functional candidate is the cytokine gene cluster located in 5q31 which harbors the genes for
interleukin (IL)-3, IL-4, IL-5, IL-9 and IL-13. These cytokines are mediators of Th2 type immune
responses and therefore good candidates for many immune-mediated diseases in which the
balance of Th1 and Th2 responses is affected. In addition to celiac disease, this gene region has
also been linked to asthma (Xu et al., 2000; Yokouchi et al., 2000; Lonjou et al., 2000; Palmer et
al., 2001; Kauppi et al., 2001) and Crohn’s disease (Rioux et al., 2001), another chronic autoimmune-
type inflammation of the small intestine.
No clear evidence for linkage in Finnish families could be detected either by our candidate approach
(II) or by the genome-wide study (V) in the 15q26 region suggested by two studies for populations
of the British Isles (Zhong et al., 1996; Houlston et al., 1997). The region is also of particular
interest, because of its involvement in type I diabetes, an autoimmune disease associated with
CD (Field et al., 1994). However, no linkage to this region has been found in any other recent
studies on CD, suggesting either the presence of a true susceptibility locus only in British
populations, or false positive findings in these original studies performed with relatively small
sample sizes.
In addition to 5q, our genome-wide analysis revealed five other HLA-unlinked regions with a weak
to moderate linkage to CD. Interestingly, linkage near to all of these regions have been reported in
at least one independent study on CD (Table 6). The regions 1p36, 4p15 and 16q12 maps close to
regions with some evidence also in studies by King et al (2000&2001). Linkage at 9p21 was
suggested in other Scandinavian populations by Naluai et al (2001). Similarly, the region 7q21
maps close both to 7q31 reported by Zhong et al (1996) and to the Williams’ Syndrome (WS)
locus at 7q11.23. WS is a rare monogenic disease resulting from a chromosomal deletion around
the elastin gene at this locus, and WS patients have an increased risk to develop celiac disease
(Giannotti et al., 2001). A previous candidate gene study at this gene locus could not however,
find any linkage evidence for CD (Grillo et al., 2000). The regions 4p, 5q and 7q were further
followed up with additional markers and 38 families. Despite the high LOD score of 3.25 obtained
at 4p15 by multipoint analysis in the original 60 families, nearly reaching the genome-wide
significance level of 3.3, the analysis in the total set of 98 families did not markedly bolster the
linkage evidence in any of these regions. This may point to the underlying heterogeneity between
the original and additional families, or alternatively, to false positive findings. As the linkage
evidence in any of these regions is not definite, subsequent confirming studies in independent
samples are needed.
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Conflictingly, the genome-wide analysis failed to show linkage on chromosomes 11q and 2q
which were suggestive in our previous candidate studies I and III. This discrepancy may result
from the enhanced power due to the larger family sample and the denser marker set used in
these former studies. There may also be slight differences between the analysis methods.
Although not significant, the obtained NPL
all scores (0.93 for 11q and 1.30 for 2q) were close
to the level of the six regions that exceeded LOD 1.0 with pseudomarker approach (unpublished
data). Furthermore, NPL
all analysis revealed two interesting regions on chromosomes 4q and
15q with nominally significant linkage (p=0.02) that remained undetected by the pseudomarker
method. This suggests that although the risk of false positive results may increase with the
multiple tests used, the comparison of the methods would be important for not losing the true
ones. Indeed, the region 4q26 has shown linkage to CD in the UK population (King et al.,
2000&2001), and 15q11 was the most promising candidate gene region in our independent
genome scan in CD families from a Finnish sub-isolate (Woolley et al., 2002). As we could not
find linkage in the candidate region 15q26 (II), located at least 80 cM telomeric from 15q11, it
will also be interesting to see whether there is two independent susceptibility factors, if any,
present on chromosome 15q, or whether the difference in the location just results from the
poor resolution of linkage approaches for a single susceptibility locus.
Conclusively, the numerous genome-wide and candidate gene analyses on celiac disease
have not yet revealed definitive evidence for any HLA-unlinked locus. The most promising
regions showing linkage in many independent studies include the chromosomes 2q, 5q and
11q which were also supported by the studies in this thesis. These regions harbor several
pathogenetically relevant candidate genes, but any disease-associated polymorphisms have
not yet been identified. Linkage evidence in all candidate regions varies from weak to moderate,
compared to the highly significant linkage scores observed in the HLA region. The HLA-unlinked
genes involved in celiac disease are therefore likely to play only a minor and obviously a more
complex role in disease susceptibility.
THE ROLE OF HLA - DOSE-EFFECT AND SEX-MODULATED RISK DUE
TO DQ2
The role of HLA-DQ in CD susceptibility was evident in the present family material. Linkage in
the HLA region on 6p23.1 was highly significant (LOD=5.96) in the 60 families studied genome-
wide, and among all members in 98 families an extremely high LOD score of 19.6 was found
at DQB1 locus. Highly significant linkage was also found in all subgroups of families divided
according to the disease phenotypes and sex (I). All but one affected individual carried either
the DQB1*02 (DQ2) or DQB1*0302 (DQ8) susceptibility alleles. The CD prevalence among all
DQB1*02 positive family members was as high as 65%. However, since the families were
selected to have multiple patients, this can not be compared with the overall population risk of
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5% among DQ2 positive individuals, if the 1% prevalence of CD (Kolho et al., 1998) and 20%
frequency of DQ2 (Partanen and Westman, 1997) are assumed. Although one copy of the
genes encoding the DQ2 molecule is enough for the disease onset, the dose dependence of
CD susceptibility due to the number of carried HLA-DQ2 molecules has been suggested in
several studies (Ploski et al., 1993; Congia et al., 1994). The difference was also seen in our
family sample: 79% of all DQB1*02 homozygotes were affected with CD, compared to the
60% prevalence among heterozygotes. Due to the non-independence of family members, the
statistical significance of this difference can not, however, be determined.
Females have a higher risk of CD than males, with a sex ratio of 2:1 (Logan, 1992), which is
a typical finding in many autoimmune diseases (Whitacre et al., 1999). The reason for this is
unknown, but hormonal differences and immunological effects of pregnancies have been
suggested. In the case of celiac disease, which often manifests with only mild or atypical
symptoms, the sex difference can also result from a lower threshold for females in going to
the clinic. This is interestingly supported by the fact that DH, which manifests with a strongly
itching and clearly visible rash, shows rather male than female overrepresentation among the
patients (Reunala, 1996). In this thesis, the sex ratio among the patients of 102 families
studied in the study I was 2.2:1, and importantly, among all HLA-DQ2 positive family members,
the risk of CD was significantly higher in females than males (p=0.0001). The high overall CD
prevalence in DQ2 positive individuals in our families is definitely biased due to the selection
of multiply affected families and the genetic non-independence of family members, but these
should not bias the comparison between the sexes. The result therefore suggests that the
DQ2 alone is a more stronger risk factor for females. Therefore, the additional genetic risk
factors could play a stronger role in the disease onset of males. This was indeed supported by
our finding that linkage at three non-HLA candidate loci was significant only in families with at
least one male patient with CD (I). Although the existence of true linkage heterogeneity could
not be equivocally proven due to small sample sizes, this may support a gain of power by
studying families with affected males.
FAILURES IN REPLICATING LINKAGE - REASONS?
Sample size. The reasons for the discrepancies between several linkage studies on CD may
lie in true heterogeneity for the disease susceptibility loci between the studied populations, or
the higher rate of false positive and negative linkage results which is a known problem in
studies of complex diseases. Under locus heterogeneity and other confounding factors in
these studies, the statistically powerful sample size required for the detection of genes with a
small effect on disease can be very large, often unrealistic for collection or study. One critical
problem in most of the linkage studies performed for CD, including ours, is the lack of power
estimations for the used family samples. However, strong linkage to the HLA region was
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observed in most of these studies. This clearly indicates that the power is high enough to
detect a locus with a strong risk effect. Power calculations for sample size needed are specific
to the risk allele prevalence and the strength of its risk effect - assumptions which are not
easy to assess for a polygenic disease. As only suggestive linkage scores are usually found
in most genome scans of any multifactorial disease, more important than reaching the
significant linkage level in an individual scan would be the support of the results by independent
studies.
Sample type and risk effects of the genes. The detection of loci with different allele frequencies
and magnitudes of risk effect can also depend on the structures of families included in the
analysis. Linkage analysis in large pedigrees are likely to be optimal for rare risk alleles with
relatively strong effect, since the probability of such an allele segregating in a large family is
increased, whereas in large collections of affected sib-pairs the heterogeneity for a rare locus
might be too high for detection of linkage. Conversely, risk alleles with a high frequency but
relatively weak effect are more likely to occur as homozygous in parents and hence, their detection
may be difficult in an analysis including a low number of large pedigrees. The larger samples of
affected sib-pairs which are also usually easier to collect, are more robust to this effect. Indeed,
the success in replication of linkage evidence among the studies on celiac disease seems to
correlate with the type of the family material used (Naluai et al., 2001). Positive evidence for
chromosomes 11p and 15q were observed only in those studies using extended, multiply affected
families, whereas in studies with affected sib-pairs, evidence for linkage in 5q and 11q was
accumulated. Indeed, the high population frequency of the known susceptibility HLA alleles can
also explain the failure to detect linkage at HLA locus in the genome-wide study with extended
pedigrees by King et al (2000), although all patients in these families carried either HLA-DQ2 or
DQ8. This was also demonstrated in our recent genome-scan for nine distantly related families
from the North-Eastern Finland, including high number of CD patients: in spite of interesting
results in a few non-HLA regions, no linkage to HLA could be detected since the number of the
segregating HLA-DQ2 haplotypes in these families was high (Woolley et al., 2002).
Comparison of the studies – meta-analysis. One current attempt to compare and combine the
results of genome scans is meta-analysis. This method can increase the power to detect loci with
a weak effect, for which the linkage scores in individual scans might have remained under the
cut-off level. However, the level of locus heterogeneity among study samples from different
populations will be higher. The effect of this to the meta-analysis remains to be seen; the risk is
always that evidence for regions observed in only some populations is going to disappear in the
combined material. A meta-analysis on Finnish (V), Italian, Swedish and British genome-wide
results is ongoing, and will hopefully strengthen the evidence for at least some of the suggested
regions and probably explain some of the discrepancies between the studies. Indeed, encouraging
evidence in favor of the chromosomes 2q, 5q and 11q has been obtained (unpublished).
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Minimization of heterogeneity – subgroups within the trait. To overcome the problem of
heterogeneity within a study material, at least two options for the sampling strategies exist.
The first can be applied to any population under study. Linkage can be tested separately in
subgroups of families divided according to any phenotypic feature of the disease (such as DH
and non-DH among celiac patients), or some already established genetic risk factor (such as
HLA-DQ in CD). This can be assumed to result from a more homogeneous genetic background
among the selected patients. The problem in this method is the decrease in the sample size,
affecting the power. Our results in publication I showed some preliminary evidence for genetic
differences between two manifestations of celiac disease, as well as between the sex of
patients. However, the determination of the disease phenotypes in celiac disease can be
problematic, since the gluten-free diet, started due to the first disease manifestation will
effectively prevent the onset of other forms of the disease. In addition, as the disease onset
can occur at any age, the follow-up of these family members in respect of genetic analyses is
difficult. This also raises the question of whether linkage methods based only on affected
individuals should be used for celiac disease. This problem of phenotypic determination can
probably be partly overtaken in future if any non-HLA gene involved in CD will be identified.
The stratification of the patients or families due to that genetic factor is very likely to help in
the search for other remaining susceptibility loci. The stratification due to the HLA susceptibility
genes is already possible, but as only a few families had patients with the DQ8 risk allele, the
division of the families into DQ2 positive and DQ2 negative groups was not meaningful in our
family sample. Instead, the classification of the patients to ‘high’ and ‘very high’ risk groups
due to the number of HLA risk alleles carried by them would be interesting, especially as our
own results supported the dose-dependent effect of CD susceptibility due to HLA-DQ2 (V).
The relative role of HLA-unlinked susceptibility genes could therefore be stronger in patients
carrying only one copy of DQ2. Indeed, a similar classification of the family sample strengthened
the linkage evidence at the CTLA4 gene region in the genome-wide scan by Naluai et al
(2001).
Minimization of heterogeneity – population choice. Since the level of heterogeneity for genetic
and environmental factors is likely to be higher in more mixed populations, another option to
minimize it is the use of isolated populations. They can be assumed to be more homogeneous
for the susceptibility genes and the founder effect present in these populations is also useful
in linkage disequilibrium based methods for positional cloning of these genes (Wright et al.,
1999). The Finnish population is a good example of a founder population, and has shown its
power in mapping studies of rare recessive monogenic diseases overpresented in Finland
(Peltonen et al., 1999). For many relatively common single gene disorders with dominant
inheritance, the strong founder effect is visible as well. These diseases often show distinct
founder mutations enriched to regional subpopulations of Finland (Kere, 2001). A good example
is familial hypercholesterolemia (FH), caused by mutations in the low-density lipoprotein (LDL)
receptor gene which leads to elevated plasma LDL levels and prematurely developed
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atherosclerosis. Approximately 1 in 500 individuals are heterozygous carriers of FH mutations
in the general population and over 600 different mutations have been described worldwide
(Ose, 1999). In Finland, four major mutations account for 75% of all FH patients and show high
differences in regional frequencies (Vuorio et al., 2001), still being rare in other Nordic countries
(Lind et al., 1998). Studies on FH have also demonstrated a wide phenotypic diversity in this
monogenic disease which was earlier considered very monotonous. In fact, it has been
suggested that most of the simple mendelian disorders are likely to have variation in the
clinical phenotype due to the other genetic background and environmental influences, thus
actually sharing many analytical problems with the multifactorial diseases (Dipple and McCabe,
2000).
The advantages of the Finnish population for studies on complex diseases still remain to be
established (Kere, 2001). Although several genome-wide studies have been performed, the
success of them can not be compared to studies in other populations as long as the actual
susceptibility alleles in these linked regions remain unidentified. Even if the total number of
involved risk loci could be assumed to be lower in Finland, the observed geographic differences
in the prevalence of some of these diseases do not directly indicate the enrichment of single
susceptibility alleles, which is the case for monogenic diseases with high penetrance.
Furthermore, the level of linkage disequilibrium in the general Finnish population may not be
significantly higher than in other populations, as opposed to the rare founder mutations of
Finnish disease heritage (Eaves et al., 2000). In our genome scan among Finnish unrelated
CD families (V), no single non-HLA region was revealed with significant linkage, which would
have been indicative for increased homogeneity of Finnish celiac families for some of the risk
genes. In fact, the scan result was very similar to most of the other scans of autoimmune
diseases, showing multiple positive peaks with weak linkage evidence, and a strong linkage
only in the HLA region. Therefore the level of homogeneity for celiac disease susceptibility
genes in the Finnish population might not differ significantly from more mixed populations.
One further way to reduce heterogeneity could be the use of sub-isolates within the Finnish
population. In addition to the assumed genetic similarity, the patiens of these are likely to
share more identical environment, which is an important factor in susceptibility to complex
disorders. Indeed, our recent genome-wide analysis for nine distantly related families with CD,
from the North-Eastern Finland, showed significant linkage in one novel region and supported
some of the findings in publication V (Woolley et al., 2002). Encouraging linkage results from
Finnish sub-isolates have been reported also for hypertension (Perola et al., 2000) and asthma
(Laitinen et al., 2001).
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CELIAC DISEASE AS A COMPLEX GENETIC DISORDER
As discussed above, the common problems of heterogeneity and other confounding factors
also complicate the genetic studies of celiac disease. However, among other autoimmune
type of diseases, celiac disease features several advantages. The major environmental trigger,
dietary gluten, is known, which is not the case for other autoimmune type of diseases. Also,
this agent is encountered by practically all individuals. The HLA association of CD is one of
the strongest among these diseases, and the functional role of the HLA risk molecules in
disease pathogenesis has been resolved. For the in situ studies, access to the affected
organ, the small intestine, is simple and can be performed safely. Since the diagnosis of CD
and many other intestinal diseases is based on small bowel biopsy, the collection of both CD
and non-CD tissue samples is relatively easy.
One drawback in studies on celiac disease is the lack of an appropriate animal model, which
are available for many other autoimmune diseases, e.g. the non-obese diabetic (NOD) mice
as a model for type I diabetes (Wicker et al., 1995), experimental autoimmune encephalomyelitis
(EAE) and neuritis (EAN) for demyelinating disorders of the nervous system (Gold et al.,
2000) and collagen-induced arthritis (CIA) for human rheumatoid arthritis (Luross and Williams,
2001). In addition to their usefulness in immunopathological studies of these diseases, the
linkage mapping of risk genes in the inbred animal strains also has several advantages over
the human studies (Risch, 2000). The level of heterogeneity can be minimized, rare disease
alleles can be fixed in the strain by positive selection in many generations, and information in
linkage analysis is very high when fully heterozygous animals from the mating of two inbred
strains are used as parents. In addition, the environment of animals is controllable and can be
standardized, and the offspring of the same litter are at an equal age and share an identical
environment. These factors will minimize the phenotypic variance of the disease due to non-
genetic factors. The linkage analyses for locating the genomic areas carrying risk factors have
shown to be powerful with these animal models and multiple regions homologous to the linked
areas in human studies have been found (Wandstrat and Wakeland, 2001). However, the
positional cloning of the actual risk genes has still remained a challenge. Alarmingly, these
animal studies have revealed an involvement of the modifier or suppressive genetic loci,
which are fully protective over the risk alleles of autoimmunity (Morel et al., 1999). Assumingly
these kind of genetic interactions are likely to underlie in human diseases as well, causing
further complexity in the search for the susceptibility genes. In spite of several advantages of
animal models, it should be kept in mind that the similar disease phenotypes of animals and
humans might not result from a fully identical genetic and pathogenetic background. Indeed,
the existence of Irish Setter dogs suffering from naturally occurring gluten sensitive enteropathy
(GSE) which resembles celiac disease and shows histologically similar reversible intestinal
injury triggered by gluten, has encouraged the researchers to investigate these dogs as model
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animals for CD (Batt et al., 1987). However, in large dog pedigrees highly affected by GSE, no
role of MHC genes could be detected (Polvi et al., 1998). Contradictory to celiac disease,
where the HLA molecules play a crucial role in disease susceptibility and pathogenesis, this
indicates that the immunopathogenetic mechanisms might differ significantly between the
dog and human diseases.
In the future, the genetic studies on celiac disease will hopefully benefit from both other fields
of studies on CD and from recent advances in modern genetics. For the past two years, a
large European consortium of 17 study groups including ours, has co-operated in order to
reveal new and reliable data on celiac disease epidemiology, pathogenetic mechanisms and
genetic susceptibility factors in a large, combined patient material. For genetic analyses, over
800 CD families have been collected by six groups. The studies on different fields of celiac
disease are also likely to support each other. The linkage evidence in a given region always
needs further studies to characterize the primary gene and allele involved with the disease,
and subsequently to prove the functional effect of this genetic factor on a given phenotype. If
this is known for any of the HLA-unlinked susceptibility genes in future, this information will
naturally provide help for the epidemiological and pathogenetic studies on CD. Novel
epidemiological data such as the disease prevalence among the carriers or concordance for
the siblings stratified for the given genetic factor will be available to collect. This can then help
to estimate the role of this factor in the total genetic background, as well as possible inheritance
models or epistatic gene-gene interactions involved with it. Together with the recent analytical
advances for e.g. simultaneous tests for multiple loci, these models will hopefully increase the
power of linkage studies in the search for the remaining susceptibility genes. Studies on the
pathogenetic mechanisms involved in celiac disease will naturally also gain advantage from
the identified genetic factors and could further suggest new functional candidate genes to test
for genetic linkage and association in family samples. With the new high-throughput microarray
approaches to study gene expression differences between affected and unaffected tissue
samples, the search for novel candidates involved in the pathogenesis or genetic susceptibility
of the disease may be feasible. The completion of human genome sequencing will offer a large
pattern of novel polymorphisms, candidate genes and accurate marker maps for genetic studies.
Together with novel cost- and labor-effective, high-throughput methods for genotyping, and
with statistical improvements such as data-mining approaches for this strongly expanding
genotypic data, the challenge of detecting even the minor susceptibility genes of complex
diseases may turn out to be a realistic task.
57
DISCUSSION
CONCLUDING REMARKS
Although the evidence for strong genetic background of celiac disease is clear, only the major
susceptibility genes at HLA-DQ have been established so far. HLA-DQ2 or DQ8 molecules are
necessary but not sufficient alone to the disease onset. In this thesis, we searched for HLA-
unlinked susceptiblity factors of celiac disease. We concentrated on previously suggested
candidate gene regions and found supporting evidence for possible susceptibility factors present
on chromosomes 5q and 11q (I), while no clear linkage was observed at 15q26 (II). We also
showed the first lines of evidence for genetic linkage between celiac disease and the CTLA4/
CD28/ICOS gene region on 2q33 (III). However, the identification of the primary disease-
associated variation in this gene region is complicated, which was demonstrated by our results
showing a high level of linkage disequilibrium within the CTLA4 gene (IV). Our genome-wide
search for the novel susceptibility loci involved in celiac disease revealed evidence for six
non-HLA regions which partially supported the findings of other studies (V). HLA still seems to
be the major risk locus and the other genetic factors may play a minor or a more complex role
in CD.The linkage results in this thesis and from other populations create together a basis for
the future search for genuine susceptibility genes at least on chromosomes 2q, 5q and 11q.
No clear advantage of concentrating on the Finnish population was seen from the genome-
wide results, suggesting that a remarkable level of heterogeneity in complex diseases may
occur even in a founder population. The linkage heterogeneity for the candidate regions was
suggested between the disease phenotypes and the sex (I). This, together with the discrepancies
between the genetic studies on celiac disease and with the observed sex- and dose-dependent
role of HLA risk factors (I, V), points to the complexity of the underlying genetic factors
involved in celiac which is likely to complicate the genetic analyses of this multifactorial
disease.
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